2 unchanged sentences
controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed
−Removed: under the Exchange Act, such as this Report, is recorded, processed, summarized, and reported within the time period specified in the
−Removed: SEC’s rules and forms.
+Added: under the Exchange Act, such as this Annual Report, is recorded, processed, summarized, and reported within the time period specified
+Added: in the SEC’s rules and forms.
Disclosure controls are also designed with the objective of ensuring that such information is accumulated
2 unchanged sentences
Our management evaluated, with the participation of our current chief executive officer and
−Removed: chief financial officer (our “ Certifying Officers ”), the effectiveness of our disclosure controls and procedures as
−Removed: of December 31, 2023, pursuant to Rule 13a-15(b) under the Exchange Act.
−Removed: Based upon that evaluation, our Certifying Officers concluded
−Removed: that, as of December 31, 2023, our disclosure controls and procedures were not effective.
+Added: chief financial officer (our “Certifying Officers”), the effectiveness of our disclosure controls and procedures as of December
+Added: 31, 2024, pursuant to Rule 13a-15(b) under the Exchange Act.
+Added: Based upon that evaluation, our Certifying Officers concluded that, as of
+Added: December 31, 2024, our disclosure controls and procedures were not effective.
do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud.
7 unchanged sentences
our control deficiencies and instances of fraud, if any.
−Removed: The design of disclosure controls and procedures also is based partly on certain
+Added: The design of disclosure controls and procedures is also based partly on certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated
1 unchanged sentence
Report on Internal Controls Over Financial Reporting
−Removed: Annual Report on Form 10-K does not include a report of management’s assessment regarding internal control over financial reporting
−Removed: or an attestation report of our independent registered public accounting firm due to a transition period established by rules of the
−Removed: SEC for newly public companies.
+Added: required by SEC rules and regulations implementing Section 404 of the Sarbanes-Oxley Act, our management is responsible for establishing
+Added: and maintaining adequate internal control over financial reporting.
+Added: Our internal control over financial reporting is designed to provide
+Added: reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for
+Added: external reporting purposes in accordance with U.S.
+Added: Our internal control over financial reporting includes those policies and procedures
+Added: to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the
+Added: assets of our company,
+Added: reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
+Added: GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors,
+Added: reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that
+Added: could have a material effect on the financial statements.
+Added: of its inherent limitations, internal control over financial reporting may not prevent or detect errors or misstatements in our financial statements.
+Added: Also, projections of any evaluation of effectiveness to future periods are subject to the risk
+Added: that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or
+Added: procedures may deteriorate.
+Added: Management assessed the effectiveness of our internal control over financial reporting as of December
+Added: In making these assessments, management used the criteria set forth by the Committee of Sponsoring Organizations of the
+Added: Treadway Commission in Internal Control — Integrated Framework (2013).
+Added: Based on our assessments and those criteria, management
+Added: determined that we did not maintain effective internal control over financial reporting as of December 31, 2024 ,
+Added: due to the material weakness in our internal controls as a result of inadequate segregation of duties within accounting processes
+Added: due to limited personnel and insufficient written policies and procedures for accounting, IT, and financial reporting and record
+Added: This Annual Report does not include an attestation
+Added: report by our independent registered public accounting firm, regarding internal control over financial reporting.
+Added: As a smaller reporting
+Added: company, our management’s report was not subject to attestation by our registered public accounting firm pursuant to rules of the
+Added: SEC that permit us to provide only management’s report in this Annual Report.
in Internal Control Over Financial Reporting
−Removed: were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange
−Removed: Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal
+Added: changes occurred in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange
+Added: Act) during the year ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.
3 unchanged sentences
following table sets forth information about our directors and executive officers.
−Removed: Fernandez Pascual
−Removed: Executive Officer, Secretary and Director
−Removed: Financial Officer and Director
−Removed: Fernandez Pascual, CEO, Secretary and Director
−Removed: Fernandez, has served as our Chief Executive Officer, Secretary and Director since May 15, 2023.
−Removed: Fernandez also serves as Secretary
−Removed: of our Sponsor.
−Removed: Pascual is a citizen and resident of Spain.
−Removed: Fernandez has most recently served as the General Manager of Chassis
−Removed: Brakes International Spain, part of Hitachi Automotive Systems since April 2019 to February 2021 and was based in San Felices de Buelna,
−Removed: Autonomía de Cantabria, Spain.
−Removed: Fernandez is COO of another SPAC entity, Genesis Unicorn Capital Corp which completed its initial
−Removed: public offering in February 2022.
−Removed: Fernandez served as the President of Gira Cluster of Automotive Industries of Cantabria from May
−Removed: 2019 to March 2021 and was based in Spain.
−Removed: From September 2018 to April 2019, Mr.
−Removed: Fernandez served as the Smart Factory Platform Leader
−Removed: of Linxens based in Levallois, Île-de-France, France.
−Removed: From January 2017 to April 2019, Mr.
−Removed: Fernandez served as the Site Director
−Removed: From September 2015 to December 2016, Mr.
−Removed: Fernandez served as the Senior Area Sales Manager Southern Europe for Quintus Technologies,
−Removed: based in Vasteras, Sweden.
−Removed: From September 2014 to September 2015, Mr.
−Removed: Fernandez served as the Site Director of Hutchinson based in Châteaudun,
−Removed: From April 2013 to August 2014, Mr.
−Removed: Fernandez served as the Production Area Manager of Gestamp based in Le Theil, Basse-Normandie,
−Removed: From November 2005 to March 2013, Mr.
−Removed: Fernandez served as Process Engineer Manager at ArcelorMittal Aviles, Spain.
−Removed: From September
−Removed: 2003 to October 2005, Mr.
−Removed: Fernandez served as Resident Engineer of ArcelorMittal based Electrolux premises in Conegliano, Veneto, Italy.
−Removed: Fernandez received his Executive MBA degree at ESCP Europe.
−Removed: Fernandez received his DEA (Master in Sciences)
−Removed: at Ecole Polytechnique.
+Added: Chief Executive
+Added: Officer, Secretary, and Director
+Added: Heung Ming Wong
+Added: Chief Financial Officer
+Added: Independent Director
+Added: Independent Director
+Added: Independent Director
+Added: Xie, CEO, Secretary, and Director
+Added: Xie has served as our chief executive officer, secretary, and director since April 2024.
+Added: Since 2017, Mr.
+Added: Xie has served as the CEO of
+Added: Hangzhou Aiwoba Network Technology Co., Ltd., a health and wellness enterprise integrating medical moxibustion, Internet of Things, artificial
+Added: intelligence and shared technology.
+Added: In his role as CEO, he is responsible for the management of the company, including developing business
+Added: plans and policies, overseeing shareholder and director meetings, supervising product development, sales and marketing, reviewing company
+Added: financial statements, and executing contracts.
+Added: Since June 2014, Mr.
+Added: Xie has also been the founder of Hangzhou Junlin Health Management
+Added: Consulting Co., Ltd., a company that offers a health moxibustion service platform with web-based and mobile applications.
+Added: as founder, Mr.
+Added: Xie manages the daily operations of the company, including setting the company’s mission and vision, raisings funds,
+Added: developing strategies, and recruiting and overseeing management teams.
+Added: Xie received his diploma from Zhejiang Vocational College
+Added: of Art in Hangzhou, China, in 2008.
+Added: We believe that Mr.
+Added: Xie is qualified to serve on our board of directors due to his experience in
+Added: managing an operating company as its CEO, as well as his experience in developing business plans and policies, raising capital, and reviewing
+Added: company financial statements.
Ming Wong, CFO, and Director
Ming Wong has served as our Chief Financial Officer and Director since May 2023.
−Removed: Wong is a citizen and resident of Hong Kong.
−Removed: Wong has over twenty years’ experience in advising multinational companies on finance, accounting, internal control and corporate
−Removed: governance matters.
−Removed: Since March 2023, Mr.
−Removed: Wong has served as an independent non-executive director of E-Home Household Service Holding
−Removed: EJH), a China-based investment holding company mainly engaged in the operation of household services.
−Removed: Since April 2022,
−Removed: he has served as an independent non-executive director of Ostin Technology Group Co., Ltd (Nasdaq:
−Removed: OST), a China-based company mainly
−Removed: engaged in the business of designing, developing and manufacturing TFT-LCD modules.
−Removed: Wong has served as an independent non-executive
−Removed: director of Helens International Holdings Company Limited (9869HK), a China-based investment holding company mainly engaged in bar operation
−Removed: and franchise business, since August 2021 and was appointed as the independent director of Sansheng Holdings (Group) Co.
−Removed: Kong Mainboard Stock Exchange listed company (stock code:
−Removed: 2183) on August 1, 2022.
Wong has also served as an independent non-executive
−Removed: director of Meihua International Medical Technologies Co., Ltd., (Nasdaq:
−Removed: MHUA) from April 2022 to June 2022.
−Removed: Wong also has served
−Removed: as a director of TD Holdings, Inc.
−Removed: GLG), a company engaged in commodity trading and supply chain services businesses, since
−Removed: From June 2020 to March 2021, Mr.
−Removed: Wong served as Chief Financial Officer of Meten EdtechX Education Group Ltd.
−Removed: a leading English language training service provider in China.
−Removed: He has served from April 2021 to April 2023 as an independent director
−Removed: of Shifang Holding Group Ltd.
−Removed: (1831HK), a Hong Kong-listed company which provides a wide range of integrated print media and digital
−Removed: media services to advertisers and since March 2020 as an independent director of Raffles Interior Ltd.
−Removed: (1376HK), a company engaged in
−Removed: the interior decoration business.
−Removed: Wong has been serving as the non-executive Chairman for Raffles Interior Ltd., a Singapore-based
−Removed: interior fitting-out services provider, since September 23, 2022.
−Removed: Previously, he also served as the Chief Financial Officer from March
−Removed: 2017 to November 2018 at Frontier Services Group (0500HK), a company listed on the Hong Kong Stock Exchange, which is a leading provider
−Removed: of integrated security, logistics, insurance and infrastructure services for clients operating in developing regions.
−Removed: Prior to that,
−Removed: Wong worked for Deloitte Touche Tohmatsu (China) and PricewaterhouseCoopers (China) for an aggregate of more than 11 years.
−Removed: graduated from the City University of Hong Kong in 1993 with a bachelor’s degree in Accountancy and obtained a master’s degree
−Removed: in Electronic Commerce from the Open University of Hong Kong in 2003.
−Removed: He is a fellow member of the association of Chartered Certified
−Removed: Accountants and the Hong Kong institute of Certified Public Accountants and a member of the Hong Kong Institute of Certified Internal
+Added: director of six other listed companies, including (i) Nature Wood Group Limited (Nasdaq:
+Added: NWGL) since September 2023;
+Added: (ii) E-Home Household
+Added: Service Holdings Ltd.
+Added: EJH) since March 2023;
+Added: (iii) Ostin Technology Group Co., Ltd.
+Added: OST) since April 2022;
+Added: International Holdings Company Limited (HKG:
+Added: 9869) since August 2021;
+Added: (v) Baiyu Holdings Inc.
+Added: (formerly known as TD Holdings, Inc.) (Nasdaq:
+Added: BYU) since April 2021;
+Added: and (vi) Raffles Interior Limited (HKG:
+Added: 1376) since March 2020.
+Added: In addition, Mr.
+Added: Wong served as an independent
+Added: non-executive director of Sansheng Holdings (Group) Co.
+Added: 2183) from August 2022 to December 2023.
+Added: From November 2010 to April
+Added: Wong was an independent non-executive director of Shifang Holding Limited (HKG:
+Added: From July 2022 to November 2023, Mr.
+Added: Wong was the independent non-executive director of REDEX Pte.
+Added: Wong has over 29 years of experience in finance, accounting, internal
+Added: controls, and corporate governance in Singapore, China, and Hong Kong.
+Added: In the PRC and Hong Kong, Mr.
+Added: Wong has helped a number of companies
+Added: listed in overseas stock exchanges, including those in the United States and Hong Kong.
+Added: From May 2020 to March 2021, Mr.
+Added: as the chief financial officer of Meten Holding Group Ltd.
+Added: Wong has also served as chief financial officer and senior
+Added: finance executive of various companies, including Frontier Services Group Limited (HKG:
+Added: 0500) from April 2017 to September 2018, and
+Added: Beijing Oriental Yuhong Waterproof Technology Co., Ltd., a leading waterproof materials manufacturer in the PRC and a company listed
+Added: on China’s Shenzhen Stock Exchange (SHE:
+Added: 2271) from May 2014 to August 2015.
+Added: Wong began his career in an international accounting
+Added: firm and moved along in audit fields by taking some senior positions both in internal and external audits including being a senior manager
+Added: and a manager in PricewaterhouseCoopers, Beijing office and Deloitte Touche Tohmatsu, Hong Kong, respectively.
+Added: Wong graduated from
+Added: the City University of Hong Kong in 1993 with a bachelor’s degree in Accounting and obtained a master’s degree in Electronic
+Added: Commerce from the Open University of Hong Kong in 2003.
+Added: He is a fellow member of the association of Chartered Certified Accountants and
+Added: the Hong Kong institute of Certified Public Accountants and a member of the Hong Kong Institute of Certified Internal Auditor.
+Added: Wong is qualified to serve on our board of directors due to his extensive experience as an independent non-executive director
+Added: as well as his more than 29 years’ experience in finance, accounting, internal control, and corporate governance.
Bao, Independent Director
−Removed: Bao is one of our independent directors.
+Added: Bao has served as one of our independent directors since November 2023.
Bao is a citizen of Canada and a resident of the PRC.
−Removed: Bao has over 15 years of experience
−Removed: in accounting and auditing.
−Removed: She has served as the Chief Financial Officer of Jayud Global Logistics Limited, a China-based end-to-end
−Removed: supply chain solution provider with a focus on providing cross-border logistics services, since October 2022.
−Removed: She has served as independent
−Removed: director of SunCar Technology Group Inc.
−Removed: since May 2023 and independent director of Cetus Capital Acquisition Corp.
+Added: Bao has over 15 years of experience in accounting and auditing.
+Added: She has served as the chief financial officer of Jayud Global Logistics
+Added: Limited, a China-based end-to-end supply chain solution provider with a focus on providing cross-border logistics services, since October
+Added: She has served as an independent director of SunCar Technology Group Inc.
+Added: since May 2023 and as an independent director of Cetus
+Added: Capital Acquisition Corp.
since February 2023.
−Removed: She served as the Chief Financial Officer of Eagsen, Inc., a vehicle communication and entertainment system provider, from April 2020
−Removed: to September 2022.
+Added: From April 2020 to September 2022, she served as the chief financial officer of Eagsen,
+Added: Inc., a vehicle communication and entertainment system provider.
Before Eagsen, Inc.
−Removed: was set up, Ms.
−Removed: Bao served as Chief Financial Officer of Shanghai Eagsen Intelligent Co., Ltd.
+Added: was established, Ms.
+Added: Bao served as Chief Financial
+Added: Officer of Shanghai Eagsen Intelligent Co., Ltd.
from November 2019 to March 2020.
From February 2018 to August 2019, Ms.
−Removed: Bao served as Chief Financial Officer of Jufeel International
−Removed: Group., a biotech company that cultivates, produces, develops and sells raw aloe vera and aloe vera based consumer products in China.
+Added: as chief financial officer of Jufeel International Group., a biotech company that cultivates, produces, develops, and sells raw aloe
+Added: vera and aloe vera based consumer products in China.
From October 2015 to January 2018, Ms.
−Removed: Bao worked as an independent consultant to provide accounting advisory services for China-based
−Removed: Bao began her career in accounting at Ernst & Young LLP Toronto, where she served from January 2005 to May 2008 as
−Removed: Bao received a bachelor’s degree in Accounting from Concordia University in 2005, and a bachelor’s degree in
−Removed: Japanese from the Beijing Second Foreign Language Institute in 1994.
−Removed: Bao is a Certified Public Accountant in the United States, and
−Removed: she is also a Canadian Chartered Professional Accountant and a Hong Kong Certified Public Accountant.
+Added: Bao worked as an independent consultant to
+Added: provide accounting advisory services for China-based companies.
+Added: Bao began her career in accounting at Ernst & Young LLP Toronto,
+Added: where she served from January 2005 to May 2008 as a senior accountant.
+Added: Bao received a bachelor’s degree in Accountancy from
+Added: Concordia University in 2004, and a bachelor’s degree in Japanese from the Beijing Second Foreign Language Institute in 1994.
+Added: Bao is a Certified Public Accountant in the United States, and she is also a Canadian Chartered Professional Accountant and a Hong Kong
+Added: Certified Public Accountant.
+Added: We believe that Ms.
+Added: Bao is qualified to serve on our board of directors due to her experience as an independent
+Added: director for a special purpose acquisition company, her extensive experience as a chief financial officer for several companies, as well
+Added: as her more than 15 years’ experience in accounting and auditing.
Julianne Huh, Independent Director
−Removed: Julianne Huh is one of our independent directors.
+Added: Julianne Huh has served as one of our independent directors since November 2023.
Huh is a citizen of Korea and resident of Malaysia.
−Removed: Since May 2021, Dr.
−Removed: been serving as Independent Director of Data Knights Acquisition Corp.
+Added: Since November 2023, Dr.
+Added: Huh has been serving as an independent director of OneMedNet Corporation (formerly known as Data Knights Acquisition
From October 2017 to June 2022, Dr.
−Removed: Huh served as the Director
−Removed: of S&I F&B Management Sdn, Bhd based in Kuala Lumpur, Malaysia, where she managed the overall business, operations and marketing
−Removed: of 2 Ox French Bistro.
+Added: Huh served as the Director of S&I F&B Management Sdn, Bhd based in Kuala Lumpur, Malaysia,
+Added: where she managed the overall business, operations and marketing of 2 Ox French Bistro.
From June 2016 to August 2017, Dr.
−Removed: Huh served as the Vice President of The
−Removed: Mall of Korea based in Bangkok, Thailand, where she managed projects for business set-up, construction of department stores and nine
−Removed: Huh also managed the overall business, operations and marketing while serving as the Vice President during this time.
+Added: as the Vice President of The Mall of Korea based in Bangkok, Thailand, where she managed projects for business set-up, construction of
+Added: department stores and nine restaurants.
+Added: Huh also managed the overall business, operations and marketing while serving as the Vice
+Added: President during this time.
From November 2013 to June 2016, Dr.
−Removed: Huh served as the Director of Business Development of Juna International Ltd based in Shanghai,
−Removed: China and Seoul, Korea, where she oversaw China Business Development in the entertainment and music industry.
−Removed: From August 2006 to June
−Removed: Huh founded the Wonderful World of Learning (WWL) and served as its General Manager based in Shanghai, where she managed the
−Removed: overall business and operations of the preschool, curriculum development and teacher training.
−Removed: From October 2011 to May 2014, Dr.
−Removed: served as the Managing Partner as well as Vice President of Pronovias Korea based in Seoul, Korea, where she launched the wedding dress
−Removed: brand “Pronovias” of the Spain flagship store as the sole franchise for the Korean market.
−Removed: Huh also oversaw and managed
−Removed: operations, marketing, PR and bi-annual buying and merchandising.
+Added: Huh served as the director of business development of Juna International
+Added: Ltd based in Shanghai, China and Seoul, Korea, where she oversaw China Business Development in the entertainment and music industry.
+Added: From August 2006 to June 2016, Dr.
+Added: Huh founded the Wonderful World of Learning (WWL) and served as its general manager based in Shanghai,
+Added: where she managed the overall business and operations of the preschool, curriculum development and teacher training.
+Added: From October 2011
+Added: to May 2014, Dr.
+Added: Huh served as the managing partner as well as vice president of Pronovias Korea based in Seoul, Korea, where she launched
+Added: the wedding dress brand “Pronovias” of the Spain flagship store as the sole franchise for the Korean market.
+Added: oversaw and managed operations, marketing, PR and bi-annual buying and merchandising.
From September 2009 to September 2019, Dr.
−Removed: Huh founded Only Natural
−Removed: Organic Bath Products based in Shanghai, China, where she was in charge of brand development and sales for charity purposes.
+Added: founded Only Natural Organic Bath Products based in Shanghai, China, where she was in charge of brand development and sales for charity
+Added: In June 2004, Dr.
Huh received her Doctor of Education (Ed.D) degree at the University of Massachusetts in the U.S.
−Removed: In May 1995, Dr.
−Removed: Huh received her
−Removed: Master of Education (M.Ed.) degree from the University of Massachusetts in the U.S.
+Added: Huh received her Master of Education (M.Ed.) degree from the University of Massachusetts in the U.S.
In June 1993, Dr.
−Removed: Huh completed two semesters of
−Removed: courses at the MBA program at the Yonsei University in Seoul, Korea.
+Added: completed two semesters of courses at the MBA program at the Yonsei University in Seoul, Korea.
In February 1991, Dr.
−Removed: Huh received her Bachelor of Arts degree in
−Removed: English Language and Literature from Ewha Women’s University in Seoul, Korea.
+Added: Huh received her
+Added: Bachelor of Arts degree in English Language and Literature from Ewha Women’s University in Seoul, Korea.
+Added: We believe that Dr.
+Added: is well-qualified to serve as a member of our board of directors due to her experience as an independent director for a special purpose
+Added: acquisition company, her extensive experience in global finance, as well as her network of contacts and relationships.
Karlsen, Independent Director
−Removed: Karlsen is one of our independent directors.
+Added: Karlsen has served as one of our independent directors since November 2023.
Karlsen is a citizen of Norway and a resident of Singapore.
2 unchanged sentences
Since June 2022, Mr.
−Removed: Karlsen has also been serving as Partner of AYA Land Development
−Removed: His main responsibility in both companies is strategic consultancy for real estate investments From December 2018 to February 2022,
−Removed: Karlsen served as the Investment Director of PIK International, where he oversaw the identification and investments of real estate
−Removed: assets in Asia.
+Added: Karlsen has also been serving
+Added: as a partner of AYA Land Development Ltd.
+Added: His main responsibility in both companies is strategic consultancy for real estate investments
+Added: From December 2018 to February 2022, Mr.
+Added: Karlsen served as the investment director of PIK International, where he oversaw the identification
+Added: and investments of real estate assets in Asia.
From June 2016 to November 2018, Mr.
−Removed: Karlsen served as Business Development Manager of CFLD International Pte.
−Removed: he was involved in business development in Asia, Middle East and Africa for industry city development.
+Added: Karlsen served as business development manager of
+Added: CFLD International Pte.
+Added: Ltd, where he was involved in business development in Asia, Middle East and Africa for industry city development.
In June 2016, Mr.
−Removed: Karlsen received
−Removed: his Master’s degree in Real Estate Finance and Investment from The University of Hong Kong.
+Added: Karlsen received his master’s degree in Real Estate Finance and Investment from The University of Hong Kong.
In May 2015, Mr.
−Removed: Karlsen received his
−Removed: Bachelor’s degree in Urban Studies from UCL Bartlett School of Planning.
+Added: Karlsen received his bachelor’s degree in Urban Studies from University College of London Bartlett School of Planning.
+Added: We believe that Mr.
+Added: Karlsen is well-qualified to serve as a member of our board of directors due to his extensive cross-border business
+Added: experience., as well as her network of contacts and relationships.
requires that a majority of our board must be composed of “independent directors,” which is defined generally as a person
32 unchanged sentences
combination will be a determining factor in our decision to proceed with any potential business combination.
−Removed: We are not party to any
+Added: We are not a party to any
agreements with our officers and directors that provide for benefits upon termination of employment.
−Removed: Committee We have established an audit committee of the board of directors.
+Added: of the Board of Directors
+Added: have established an audit committee of the board of directors.
Lin Bao, Robin H.
−Removed: Karlsen and Julianne Huh serve as members
−Removed: of our audit committee.
+Added: Karlsen, and Julianne Huh serve as members of our audit
Lin Bao chairs the audit committee.
−Removed: Under the Nasdaq listing standards and applicable SEC rules, we are required
−Removed: to have three members of the audit committee all of whom must be independent.
+Added: Under the Nasdaq listing standards and applicable SEC rules, we are required to have three
+Added: members of the audit committee all of whom must be independent.
Lin Bao, Robin H.
Karlsen and Julianne Huh are independent.
−Removed: member of the audit committee is financially literate and our board of directors has determined that Lin Bao qualifies as an “audit
−Removed: committee financial expert” as defined in applicable SEC rules.
+Added: of the audit committee is financially literate and our board of directors has determined that Lin Bao qualifies as an “audit committee
+Added: financial expert” as defined in applicable SEC rules.
Responsibilities
19 unchanged sentences
standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities.
−Removed: The members of our Compensation Committee are Lin Bao, Robin H.
+Added: members of our Compensation Committee are Lin Bao, Robin H.
Karlsen, and Julianne Huh.
−Removed: Julianne Huh chairs the compensation
+Added: Julianne Huh chairs the compensation committee.
We have adopted a compensation committee charter, which detail the principal functions of the compensation committee, including:
36 unchanged sentences
of Conduct and Ethics
−Removed: have adopted a code of conduct and ethics applicable to our directors, officers and employees in accordance with applicable federal securities
−Removed: We filed a copy of our form of Code of Ethics and our audit committee charter as exhibits to the registration statement in connection
−Removed: with our IPO.
−Removed: You will be able to review these documents by accessing our public filings at the SEC’s web site at www.sec.gov .
+Added: have adopted a code of conduct and ethics applicable to our directors, officers, and employees in accordance with applicable federal
+Added: securities laws.
+Added: We filed a copy of our form of Code of Ethics and our audit committee charter as exhibits to the registration statement
+Added: in connection with our IPO.
+Added: You will be able to review these documents by accessing our public filings at the SEC’s web site at
+Added: www.sec.gov .
In addition, a copy of the Code of Ethics will be provided without charge upon request from us.
−Removed: We intend to disclose any amendments
−Removed: to or waivers of certain provisions of our Code of Ethics in a Current Report on Form 8-K.
−Removed: See “ Where You Can Find Additional
−Removed: Information .”
−Removed: investors should be aware of the following potential conflicts of interest:
−Removed: of our officers or directors is required to commit his or her full time to our affairs and, accordingly, may have conflicts of interest
−Removed: in allocating his or her time among various business activities.
−Removed: the course of their other business activities, our officers and directors may become aware of investment and business opportunities
−Removed: which may be appropriate for presentation to us as well as the other entities with which they are affiliated.
−Removed: Our management may
−Removed: have conflicts of interest in determining to which entity a particular business opportunity should be presented.
−Removed: May 1, 2023, our initial shareholders purchased founder shares and on December 6, 2023, our sponsor purchased the private units in
−Removed: transactions that closed simultaneously with the closing of our IPO.
−Removed: Our initial shareholders have agreed to waive their right to
−Removed: liquidating distributions with respect to its founder shares if we fail to consummate our initial business combination within the
−Removed: required time period.
−Removed: However, if our initial shareholders acquire public shares in or after our IPO, they will be entitled to receive
−Removed: liquidating distributions with respect to such public shares if we fail to consummate our initial business combination within the
−Removed: required time period.
−Removed: If we do not complete our initial business combination within such applicable time period, the proceeds of
−Removed: the sale of the private units will be used to fund the redemption of our public shares, and the private units will expire worthless.
−Removed: officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention
−Removed: or resignation of any such officers and directors was included by a target business as a condition to any agreement with respect
−Removed: to our initial business combination.
+Added: We intend to disclose
+Added: any amendments to or waivers of certain provisions of our Code of Ethics in a Current Report on Form 8-K.
+Added: See “ Where You Can
+Added: Find Additional Information .”
+Added: Recovery and Clawback Policies
+Added: the Sarbanes-Oxley Act, in the event of misconduct that results in a financial restatement that would have reduced a previously paid
+Added: incentive amount, we can recoup those improper payments from our executive officers.
+Added: The SEC also recently adopted rules which direct
+Added: national stock exchanges to require listed companies to implement policies intended to recoup bonuses paid to executives if we are found
+Added: to have misstated its financial results.
+Added: have adopted a compensation recovery policy (the “Clawback Policy”) effective as of November 30, 2023 that complies with
+Added: the Nasdaq’s new clawback rules promulgated under the SEC’s Rule 10D-1.
+Added: Clawback Policy provides for the mandatory recovery of erroneously awarded incentive-based compensation from our current and former executive
+Added: officers as defined in the Rule (“Covered Executives”) in the event that we are required to prepare an accounting restatement
+Added: due to our material noncompliance with any financial reporting requirement under the securities laws.
+Added: The recovery of such compensation
+Added: applies regardless of whether a Covered Executive engaged in misconduct or otherwise caused or contributed to the requirement of an accounting
+Added: Under the Clawback Policy, our board of directors may recoup from the Covered Executives erroneously awarded incentive compensation
+Added: received within a lookback period of the three completed fiscal years preceding the date on which we are required to prepare an accounting
+Added: foregoing description of the Clawback Policy does not purport to be complete and is qualified in its entirety by the terms and conditions
+Added: of the Clawback Policy, a copy of which is filed as Exhibit 97.1 to our annual report on Form 10-K for the fiscal year ended December
+Added: 31, 2023 and is incorporated herein by reference.
Cayman Islands law, directors and officers owe the following fiduciary duties:
6 unchanged sentences
This duty has been defined as a requirement
−Removed: to act as a reasonably diligent person having both the general knowledge, skill and experience that may reasonably be expected of a person
−Removed: carrying out the same functions as are carried out by that director in relation to the company and the general knowledge skill and experience
−Removed: which that director has.
+Added: to act as a reasonably diligent person having both the general knowledge, skill, and experience that may reasonably be expected of a
+Added: person carrying out the same functions as are carried out by that director in relation to the company and the general knowledge skill
+Added: and experience which that director has.
set out above, directors have a duty not to put themselves in a position of conflict and this includes a duty not to engage in self-dealing,
24 unchanged sentences
he might have.
−Removed: 16(a) Beneficial Ownership Reporting Compliance
−Removed: 16(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, requires our executive officers, directors and persons
−Removed: who beneficially own more than 10% of a registered class of our equity securities to file with the Securities and Exchange Commission
−Removed: initial reports of ownership and reports of changes in ownership of our shares of common stock and other equity securities.
−Removed: These executive
−Removed: officers, directors, and greater than 10% beneficial owners are required by SEC regulation to furnish us with copies of all Section 16(a)
−Removed: forms filed by such reporting persons.
−Removed: solely on our review of such forms furnished to us and written representations from certain reporting persons, we believe that all filing
−Removed: requirements applicable to our executive officers, directors and greater than 10% beneficial owners were filed in a timely manner.
+Added: is a table summarizing the entities to which our officers and directors currently have fiduciary duties or contractual obligations:
+Added: Entity/company
+Added: Business/industry
+Added: Affiliation/Position
+Added: Director/Managing
+Added: Director/Chairman/
+Added: Aiwoba Network Technology Co., Ltd.
+Added: Junlin Health Management Consulting Co., Ltd.
+Added: Household Service Holding Ltd.
+Added: Holdings (Group) Co.
+Added: Technology Group Co., Ltd.
+Added: panel manufacturing
+Added: International Holdings Company Limited
+Added: Holdings, Inc.
+Added: resources online trading
+Added: Interiors Limited
+Added: Land Development Corp.
+Added: Estate Developer
+Added: Global Logistics Limited
+Added: chain solution provider
+Added: Capital Acquisition Corp.
+Added: Technology Group Inc.
+Added: automotive after-sales
+Added: further minimize conflicts of interest, we have agreed not to consummate an initial business combination with an entity that is affiliated
+Added: with any of our Initial Shareholders, officers, or directors unless we have obtained an opinion from an independent investment banking
+Added: firm, or another independent entity that commonly renders valuation opinions, and the approval of a majority of our disinterested independent
+Added: directors that the business combination is fair to our company (or shareholders) from a financial point of view.
+Added: Notwithstanding the
+Added: foregoing, our amended and restated memorandum and articles of association provides that, subject to fiduciary duties under Cayman Islands
+Added: law, we renounce our interest in any corporate opportunity offered to any director or officer unless such opportunity is expressly offered
+Added: to such person solely in his or her capacity as a director or officer of our company and such opportunity is one we are legally and contractually
+Added: permitted to undertake and would otherwise be reasonable for us to pursue.
+Added: officers and directors, as well as our Initial Shareholders, have agreed, pursuant to the terms of a letter agreement entered into with
+Added: us, (i) to vote any Founder Shares and Private Shares held by them in favor of any proposed business combination and (ii) not to redeem
+Added: such shares in connection with a shareholder vote to approve a proposed initial business combination or any amendment to our charter
+Added: documents prior to the consummation of our initial business combination or sell any shares to us in a tender offer in connection with
+Added: a proposed initial business combination.
+Added: on Liability and Indemnification of Officers and Directors
+Added: Islands law does not limit the extent to which a company’s memorandum and articles of association may provide for indemnification
+Added: of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public
+Added: policy, such as to provide indemnification against willful default, fraud or the consequences of committing a crime.
+Added: Our amended and
+Added: restated memorandum and articles of association provides for indemnification of our (former and existing) officers and directors (“Indemnified
+Added: Persons”) to the maximum extent permitted by law against all actions, proceedings, costs, charges, expenses, losses, damages or
+Added: liabilities incurred or sustained in or about the conduct of the company’s business or affairs or in the execution or discharge
+Added: of the Indemnified Person’s duties, powers, authorities or discretions.
+Added: This includes all costs, expenses, losses or liabilities
+Added: incurred by the Indemnified Person in defending (whether successfully or otherwise) any civil, criminal, administrative or investigative
+Added: proceedings (whether threatened, pending or completed) concerning the company or its affairs in any court or tribunal, whether in the
+Added: Cayman Islands or elsewhere.
+Added: However, no Indemnified Person shall be indemnified in respect of any matter arising out of his own actual
+Added: fraud, willful default or willful neglect.
+Added: We may purchase a policy of directors’ and officers’ liability insurance that
+Added: insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures
+Added: us against our obligations to indemnify our officers and directors.
+Added: as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us
+Added: pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy
+Added: as expressed in the Securities Act and is therefore unenforceable.
Executive Compensation.
21 unchanged sentences
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
−Removed: following table sets forth as of March 22, 2024 the number of our ordinary shares beneficially owned by (i) each person who is known
−Removed: by us to be the beneficial owner of more than five percent of our issued and outstanding ordinary shares (ii) each of our officers
+Added: following table sets forth the number of our ordinary shares beneficially owned, as of March 28, 2025 by (i) each person who is
+Added: known by us to be the beneficial owner of more than five percent of our issued and outstanding ordinary shares;
+Added: (ii) each of our officers
and directors;
and (iii) all of our officers and directors as a group.
−Removed: As of March 22, 2024, we had 9,026,000 shares of common
−Removed: stock, issued and outstanding.
−Removed: otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all shares
−Removed: of common stock beneficially owned by them.
−Removed: The following table does not reflect record of beneficial ownership of any shares of common
−Removed: stock issuable upon exercise of the warrants or conversion of rights, as the warrants are not exercisable, and the rights are not convertible
−Removed: within 60 days of March 22, 2024.
+Added: As of March 28, 2025, we had 6,121,733 ordinary shares issued
+Added: and outstanding.
+Added: otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to the ordinary
+Added: shares beneficially owned by them.
and Address of Beneficial Owner (1)
of Shares Beneficially Owned (2)
−Removed: of Outstanding Shares
−Removed: Juan Fernandez
+Added: Percentage of
+Added: Outstanding Shares
Heung Ming Wong
+Added: Juan Fernandez Pascual (3)
and directors as a group
2 unchanged sentences
Aimei Investment Ltd (4)
−Removed: Harraden Circle Investments
−Removed: Cowen and Company, LLC (5)
−Removed: Glazer Capital, LLC (6)
−Removed: Wealthspring Capital LLC (7)
+Added: First Trust Merger Arbitrage
+Added: First Trust Capital Management
+Added: Wolverine Asset Management,
+Added: Karpus Investment Management (8)
than one percent.
2 unchanged sentences
not include beneficial ownership of any shares of common stock underlying outstanding private rights, as such shares are not issuable
−Removed: within 60 days of the date of this report.
−Removed: shares held by our sponsor.
−Removed: Huang Han has voting and dispositive power over the shares held of record by our sponsor.
−Removed: disclaims any beneficial ownership of the shares held by our sponsor, except to the extent of her pecuniary interest therein.
−Removed: address of Aimei Investment Ltd.
−Removed: Is 4th Floor, Harbour Place, 103 South Church Street, P.O.
−Removed: Box 10240, Grand Cayman KY1-1002, George
−Removed: Town, Cayman Islands.
−Removed: on a Schedule 13G filed on January 31, 2024.
−Removed: The schedule relates to shares directly beneficially
−Removed: owned by Harraden Circle Investors, LP (“Harraden Fund”).
−Removed: Harraden Circle Investors
−Removed: GP, LP (“Harraden GP”) is the general partner to Harraden Fund, and Harraden
−Removed: Circle Investors GP, LLC (“Harraden LLC”) is the general partner of Harraden
−Removed: Harraden Circle Investments, LLC “Harraden Advisor”) serves as investment
−Removed: manager to Harraden Fund.
−Removed: Fortmiller, Jr.
−Removed: is the managing member of each of
−Removed: Harraden LLC and Harraden Adviser.
−Removed: In such capacities, each of Harraden GP, Harraden LLC,
−Removed: Harraden Adviser and Mr.
−Removed: Fortmiller may be deemed to indirectly beneficially own the shares
−Removed: reported directly beneficially owned by Harraden Fund.
−Removed: The address of the principal business
−Removed: office of each reporting person is 299 Park Avenue, 21st Floor, New York, NY 10171.
−Removed: on a Schedule 13G filed on February 2, 2024.
−Removed: The address of the principal business office of the reporting person is 599 Lexington
−Removed: Ave, New York, NY 10022.
−Removed: The report does not name a natural person who directly or indirectly exercises sole or shared voting and/or
−Removed: dispositive power with respect to the securities.
−Removed: The report is signed by John Holmes, Chief Operating Officer.
−Removed: on a Schedule 13G filed on February 14, 2024.
−Removed: Glazer serves as the Managing Member of Glazer Capital LLC.
−Removed: of the business office of each of the reporting persons is 250 West 55th Street, Suite 30A, New York, New York 10019.
−Removed: on a Schedule 13G filed on February 14, 2024.
−Removed: The statement was filed jointly filed by Wealthspring Capital LLC and Matthew Simpson,
−Removed: who is a United States citizen and a manager of Wealthspring.
−Removed: The principal business address for Wealthspring and for Mr.
−Removed: is 2 Westchester Park Drive, Suite 108, West Harrison, NY 10604.
+Added: within 60 days of the date of this Annual Report.
+Added: April 15, 2024, Juan Fernandez Pascual resigned as chief executive officer, secretary, and director of our Company, effective immediately.
+Added: On April 19, 2024, our board or directors appointed Junheng Xie as our chief executive officer, secretary, and director with effect
+Added: from April 15, 2024.
+Added: shares held by Aimei Investment Ltd, our Sponsor.
+Added: Huang Han, who is the sole shareholder and director of the Sponsor, has voting
+Added: and dispositive power over the shares held of record by our Sponsor.
+Added: The business address of Aimei Investment Ltd is Ogier Global
+Added: (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, George Town, Cayman Islands.
+Added: on a Schedule 13G filed on November 14, 2024.
+Added: The schedule was filed jointly by First Trust Merger Arbitrage Fund (“VARBX”),
+Added: First Trust Capital Management L.P.
+Added: (“FTCM”), First Trust Capital Solutions L.P.
+Added: (“FTCS”) and FTCS Sub GP
+Added: LLC (“Sub GP”).
+Added: FTCM is an investment adviser registered with the SEC that provides investment advisory services to,
+Added: among others, (i) series of Investment Managers Series Trust II, an investment company registered under the Investment Company Act
+Added: of 1940, specifically First Trust Multi-Strategy Fund and VARBX, (ii) First Trust Alternative Opportunities Fund, an investment company
+Added: registered under the Investment Company Act of 1940, and (iii) Highland Capital Management Institutional Fund II, LLC, a Delaware
+Added: limited liability company (collectively, the “Client Accounts”).
+Added: FTCS is a Delaware limited partnership and control person
+Added: Sub GP is a Delaware limited liability company and control person of FTCM.
+Added: VARBX is a series of Investment Managers Series
+Added: Trust II, an investment company registered under the Investment Company Act of 1940.
+Added: As investment adviser to the Client Accounts,
+Added: FTCM has the authority to invest the funds of the Client Accounts in securities (including our ordinary shares) as well as the authority
+Added: to purchase, vote and dispose of securities, and may thus be deemed the beneficial owner of the ordinary shares of our Company held
+Added: in the Client Accounts.
+Added: According to the schedule, Joy Ausili is the Trustee, Vice President and Assistant Secretary of VARBX.
+Added: principal business address of VARBX is 235 West Galena Street, Milwaukee, WI 53212.
+Added: on a Schedule 13G filed on November 14, 2024.
+Added: The schedule was filed jointly by First Trust Merger Arbitrage Fund (“VARBX”),
+Added: First Trust Capital Management L.P.
+Added: (“FTCM”), First Trust Capital Solutions L.P.
+Added: (“FTCS”) and FTCS Sub GP
+Added: LLC (“Sub GP”).
+Added: FTCM is an investment adviser registered with the SEC that provides investment advisory services to,
+Added: among others, (i) series of Investment Managers Series Trust II, an investment company registered under the Investment Company Act
+Added: of 1940, specifically First Trust Multi-Strategy Fund and VARBX, (ii) First Trust Alternative Opportunities Fund, an investment company
+Added: registered under the Investment Company Act of 1940, and (iii) Highland Capital Management Institutional Fund II, LLC, a Delaware
+Added: limited liability company.
+Added: FTCS is a Delaware limited partnership and control person of FTCM.
+Added: Sub GP is a Delaware limited liability
+Added: company and control person of FTCM.
+Added: FTCS and Sub GP may be deemed to control FTCM and therefore may be deemed to be beneficial owners
+Added: of the ordinary shares owned by FTCM.
+Added: According to the schedule, Chad Eisenberg is the chief operating officer of FTCM, FTCS, and
+Added: The principal business address of FTCM, FTCS and Sub GP is 225 W.
+Added: Wacker Drive, 21st Floor, Chicago, IL 60606.
+Added: on a Schedule 13G filed on October 16, 2024 and a Schedule 13G/A filed on January 31, 2025.
+Added: The schedule relates to shares owned
+Added: by Wolverine Asset Management, LLC (“WAM”).
+Added: The sole member and manager of WAM is Wolverine Holdings, L.P.
+Added: Bellick and Christopher L.
+Added: Gust may be deemed to control Wolverine Trading Partners, Inc., the general
+Added: partner of Wolverine Holdings.
+Added: The address of the principal business office of WAM is 175 West Jackson Boulevard, Suite 340, Chicago,
+Added: on a Schedule 13G filed on April 9, 2024.
+Added: Karpus Investment Management (“Karpus”) is controlled by City of London Investment
+Added: Group plc (“CLIG”), which is listed on the London Stock Exchange.
+Added: However, in accordance with SEC Release No.
+Added: (January 12, 1998), effective informational barriers have been established between Karpus and CLIG such that voting and investment
+Added: power over the subject securities is exercised by Karpus independently of CLIG, and, accordingly, attribution of beneficial ownership
+Added: is not required between Karpus and CLIG.
+Added: The address of the principal business office for Karpus is 183 Sully’s Trail, Pittsford,
+Added: New York 14534.
Certain Relationships and Related Transactions, and Director Independence.
−Removed: to the IPO, the Company issued an aggregate of 50,000 ordinary shares of $1.00 par value each to Han Huang.
−Removed: On May 11, 2023, Han Huang
−Removed: transferred those ordinary shares to the sponsor and on May 15, 2023 the sponsor resolved to sub-divide the ordinary shares of $1.00
−Removed: par value each into ordinary shares of $0.0001 par value each and as such the sponsor held 500,000,000 ordinary shares of $0.0001 each.
−Removed: On May 15, 2023 the directors resolved to repurchase 498,562,500 ordinary shares from the sponsor, the repurchase resulting in the sponsor
−Removed: holding 1,437,500 ordinary shares.
−Removed: On May 25, 2023, 1,437,500 founder shares were issued to the sponsor (up to 187,500 of which are subject
−Removed: to forfeiture depending on the extent to which the underwriters’ over-allotment option is exercised) pursuant to a securities subscription
−Removed: agreement and the 1,437,500 ordinary shares previously held by the sponsor were repurchased by the company, the shares have been retroactively
−Removed: On October 20, 2023, the Company capitalized an amount equal to $28.75 standing to the credit of the share premium account
−Removed: and appropriated such sum and applied it on behalf of the Sponsor towards paying up in full (as to the full par value of $0.0001 per
−Removed: founder share) 287,500 unissued ordinary shares of $0.0001 par value and allotted such shares credited as fully paid to the Sponsor,
−Removed: resulting in 1,725,000 shares being issued and outstanding.
−Removed: 225,000 shares of such ordinary shares are not subject to forfeiture as the
−Removed: underwriters’ over-allotment was exercised in full.
−Removed: The initial shareholders will collectively own approximately 20% of the Company’s
−Removed: issued and outstanding shares after the Initial public Offering (assuming the initial shareholders do not purchase any Public Shares
−Removed: in the Initial Public Offering and excluding the Private Units and underlying securities).
+Added: to the IPO, we issued an aggregate of 50,000 ordinary shares of $1.00 par value each to Han Huang, who is the director of our Sponsor.
+Added: On May 11, 2023, Han Huang transferred those ordinary shares to the Sponsor and, on May 15, 2023, the Sponsor resolved to sub-divide
+Added: the ordinary shares of $1.00 par value each into ordinary shares of $0.0001 par value each and, as a result, the Sponsor held 500,000,000
+Added: ordinary shares of $0.0001 each.
+Added: On May 15, 2023, the directors resolved to repurchase 498,562,500 ordinary shares from the Sponsor,
+Added: the repurchase resulting in the Sponsor holding 1,437,500 ordinary shares.
+Added: On May 25, 2023, 1,437,500 Founder Shares were issued to the
+Added: Sponsor pursuant to a securities subscription agreement.
+Added: Simultaneously, the 1,437,500 ordinary shares previously held by the Sponsor
+Added: were repurchased by us.
+Added: These share transactions have been retroactively adjusted.
+Added: of May 8, 2023, $25,000 was included as a subscription receivable.
+Added: On September 15, 2023, we received $25,000 from the Sponsor in cash.
+Added: The Sponsor transferred 152,000 of those ordinary shares among our then-chief executive officer, chief financial officer, and three independent
+Added: directors at their original purchase price pursuant to executed securities assignment agreements, effective as of May 25, 2023.
+Added: October 20, 2023, we capitalized an amount equal to $28.75 standing to the credit of the share premium account and appropriated such
+Added: sum and applied it on behalf of the Sponsor towards paying up in full (as to the full par value of $0.0001 per Founder Share) 287,500
+Added: unissued ordinary shares of $0.0001 par value, and allotted such shares credited as fully paid to the Sponsor, resulting in 1,725,000
+Added: shares being issued and outstanding.
+Added: 225,000 shares of such ordinary shares are not subject to forfeiture as the underwriters’
+Added: over-allotment was exercised in full.
to certain limited exceptions, the Initial Shareholders have agreed not to transfer, assign or sell their Founder Shares until six months
−Removed: after the date of the consummation of our initial business combination or earlier if, subsequent to initial business combination, the
−Removed: Company consummate a subsequent liquidation, merger, share exchange or other similar transaction which results in all of the shareholders
−Removed: having the right to exchange their ordinary shares for cash, securities or other property.
+Added: after the date of the consummation of our initial business combination or earlier if, subsequent to initial business combination, we
+Added: consummate a subsequent liquidation, merger, share exchange or other similar transaction which results in all of the shareholders having
+Added: the right to exchange their ordinary shares for cash, securities or other property.
Note — Related Party
−Removed: May 1, 2023, the Sponsor issued an unsecured promissory note to the Company, pursuant to which the Company may borrow up to an aggregate
−Removed: principal amount of $750,000, to be used for payment of costs related to the IPO.
−Removed: The note is non-interest bearing and payable on the
−Removed: earlier of (i) December 31, 2023, (ii) the consummation of the IPO or (iii) the date on which the Company determines to not proceed with
−Removed: As of December 6, 2023, the Company has borrowed $210,151 under the promissory note with our Sponsor.
−Removed: This promissory note was
−Removed: fully repaid on December 7, 2023.
−Removed: There was no balance due as of December 31, 2023.
+Added: May 1, 2023, the Sponsor issued an unsecured promissory note to us, pursuant to which we may borrow up to an aggregate principal amount
+Added: of $750,000, to be used for payment of costs related to the IPO.
+Added: The note is non-interest bearing and payable on the earlier of (i) December
+Added: 31, 2023, (ii) the consummation of the IPO, or (iii) the date on which we determine to not proceed with the IPO.
+Added: As of December 6, 2023,
+Added: we had borrowed $210,151 under the promissory note with the Sponsor.
+Added: This promissory note was fully repaid on December 7, 2023.
+Added: was no balance due as of December 31, 2024.
+Added: Loan — Related Party
+Added: December 11, 2024 and January 13, 2025, the Sponsor and United Hydrogen caused the first and second monthly extension fee of $227,700
+Added: (equivalent to $0.033 per Public Share), respectively, to be deposited into the Trust Account, to extend the date by which we have to
+Added: consummate a business combination from December 6, 2024 to February 6, 2025.
+Added: On February 6, 2025 and March 6, 2025, the Sponsor and United
+Added: Hydrogen caused the third and fourth monthly extension fee of $150,000, respectively, to be deposited into the Trust Account, to further
+Added: extend the deadline from February 6, 2024 to April 6, 2025.
+Added: The deposit of the first, second, third, and fourth monthly extension fee
+Added: is evidenced by an unsecured promissory note (each, a “Monthly Extension Promissory Note”).
+Added: The first and second Monthly
+Added: Extension Promissory Notes are in the principal amount of $227,700 each, shared equally between the Sponsor and United Hydrogen ($113,850
+Added: The third and fourth Monthly Extension Promissory Notes are in the principal amount of $150,000, also shared equally between the
+Added: Sponsor and United Hydrogen ($75,000 each).
+Added: Each Monthly Extension Promissory Note bears no interest and is payable in full upon the
+Added: consummation of the Business Combination.
+Added: The Sponsor and United Hydrogen have the right, but not the obligation, to convert the Monthly
+Added: Extension Promissory Note, in whole or in part, into our private units, at a price of $10.00 per unit, each consisting of one ordinary
+Added: share and one right to receive one-fifth (1/5) of one ordinary share of our Company, immediately prior to the consummation of the Business
+Added: Combination, by providing us with written notices of their intention to convert the Monthly Extension Promissory Note at least two business
+Added: days prior to the closing of the Business Combination.
+Added: As of December 31, 2024 and 2023, the note payable balance was $227,700 and $0,
+Added: respectively.
Administrative
Services Arrangement
−Removed: affiliate of our Sponsor has agreed, commencing from the date that the Company’s securities were first listed on Nasdaq, through
−Removed: the earlier of the Company’s consummation of a Business Combination and its liquidation, to make available to the Company our Sponsor
−Removed: certain general and administrative services, including office space, utilities and administrative services, as the Company may require
−Removed: from time to time.
−Removed: The Company has agreed to pay to the affiliate of our Sponsor, $10,000 per month, for up to 12 months, subject to
−Removed: extension to up to 24 months for such administrative services.
−Removed: order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor or an affiliate of the Sponsor,
−Removed: or the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“ Working
+Added: Sponsor has agreed, commencing from the date that our securities were first listed on Nasdaq, through the earlier of our consummation
+Added: of an initial business combination and our liquidation, to make available to us certain general and administrative services, including
+Added: office space, utilities, and administrative services, as we may require from time to time.
+Added: We have agreed to pay to the Sponsor, $10,000
+Added: per month, for up to 12 months, subject to extension to up to 24 months, for such administrative services.
+Added: As of December 31, 2024 and
+Added: 2023, the unpaid balance was $120,000 and $0, respectively, which was included in amount due to related party balance.
+Added: order to finance transaction costs in connection with a business combination, the Sponsor, the affiliates of the Sponsor, or our officers
+Added: and directors may, but are not obligated to, make loans from time to time to us to fund certain capital requirements (“Working
Capital Loans”).
4 unchanged sentences
In the event that a business combination does
−Removed: not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds
−Removed: held in the Trust Account would be used to repay the Working Capital Loans.
−Removed: As of December 31, 2023, no amounts under such loans have
+Added: not close, we may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in
+Added: the Trust Account would be used to repay the Working Capital Loans.
+Added: As of December 31, 2024 and 2023, there were no amounts outstanding
+Added: under any Working Capital Loans.
+Added: to Related Company
+Added: of December 31, 2024 and 2023, the Company had a total amount due to related company of $289,780 and $0, from a related party, respectively,
+Added: for the payment of costs related to general and administrative services, the Initial Public Offering, and administrative services agreement.
+Added: The balance of which $50,000 was deposited in the Trust Account as of December 31, 2024 for the January 13, 2025 extension payment.
+Added: balance is unsecured, interest-free and has no fixed terms of repayment.
ongoing and future transactions between us and any member of our management team or his or her respective affiliates will be on terms
15 unchanged sentences
“— Part III, Item 10 - Directors, Executive Officers and Corporate Governance.”
−Removed: PRINCIPAL ACCOUNTANT FEES AND SERVICES.
+Added: Principal Accounting Fees and Services.
following is a summary of fees paid or to be paid to MaloneBailey, LLP, or MaloneBailey, for services rendered.
−Removed: Audit fees consist of fees for professional services rendered for the audit of our year-end financial statements and
+Added: Audit fees consist of fees billed for professional services rendered for the audit of our year-end financial statements and
services that are normally provided by MaloneBailey in connection with regulatory filings.
−Removed: The aggregate fees of MaloneBailey for
−Removed: professional services rendered for the audit of our annual financial statements, review of the financial information included in our
−Removed: Forms 8-K for the respective periods and other required filings with the SEC totaled approximately $115,000 for the period
−Removed: from April 27, 2023 (inception) through December 31, 2023.
−Removed: The above amounts include interim procedures and audit fees,
−Removed: as well as attendance at audit committee meetings.
+Added: The aggregate fees billed by MaloneBailey
+Added: for professional services rendered for the audit of our annual financial statements, review of the financial information included in
+Added: our required filings with the SEC for the year ended December 31, 2024 and for the period from April 27, 2023 (inception) through December
+Added: 31, 2023 totaled $160,000 and $115,000, respectively.
+Added: The above amounts include interim procedures and audit fees, as well as attendance
+Added: at audit committee meetings.
Audit-Related
−Removed: Audit-related fees consist of fees billed for assurance and related services that are reasonably related to performance of
−Removed: the audit or review of our financial statements and are not reported under “Audit Fees.” These services include attest services
−Removed: that are not required by statute or regulation and consultations concerning financial accounting and reporting standards.
−Removed: For the period
−Removed: from April 27, 2023 (inception) through December 31, 2023, we did not pay MaloneBailey any audit-related fees.
−Removed: We have not paid MaloneBailey any fee for tax return services, planning and tax advice for the period from April 27, 2023 (inception) through
−Removed: December 31, 2023.
−Removed: We did not pay MaloneBailey for any other services for the period from April 27, 2023 (inception) through December 31, 2023.
−Removed: audit committee was formed upon the consummation of our Initial Public Offering.
−Removed: As a result, the audit committee did not preapprove
−Removed: all of the foregoing services, although any services rendered prior to the formation of our audit committee were approved by our board
−Removed: of directors.
−Removed: Since the formation of our audit committee, and on a going-forward basis, the audit committee has and will preapprove all
−Removed: auditing services and permitted non-audit services to be performed for us by our auditors, including the fees and terms thereof (subject
−Removed: to the de minimis exceptions for non-audit services described in the Exchange Act which are approved by the audit committee prior to
−Removed: the completion of the audit).
−Removed: EXHIBITS AND CONSOLIDATED FINANCIAL STATEMENT SCHEDULES
−Removed: following documents are filed as part of this report:
+Added: Audit-related services consist of fees billed for assurance and related services that are reasonably related to performance
+Added: of the audit or review of our financial statements and are not reported under “Audit Fees.” These services include attest
+Added: services that are not required by statute or regulation and consultations concerning financial accounting and reporting standards.
+Added: did not pay MaloneBailey for consultations concerning financial accounting and reporting standards for the period for the year ended
+Added: December 31, 2024 and for the period from April 27, 2023 (inception) through December 31, 2023.
+Added: We did not pay MaloneBailey for tax planning and tax advice for the year ended December 31, 2024 and for the period from April
+Added: 27, 2023 (inception) through December 31, 2023.
+Added: We did not pay MaloneBailey for other services for the year ended December 31, 2024 and for the period from April 27,
+Added: 2023 (inception) through December 31, 2023.
+Added: audit committee was formed in connection with the effectiveness of our registration statement for our IPO.
+Added: As a result, the audit committee
+Added: did not pre-approve all of the foregoing services, although any services rendered prior to the formation of our audit committee were
+Added: approved by our board of directors.
+Added: Since the formation of our audit committee, and on a going-forward basis, the audit committee has
+Added: and will pre-approve all audit services and permitted non-audit services to be performed for us by our auditors, including the fees and
+Added: terms thereof (subject to the de minimis exceptions for non-audit services described in the Exchange Act which are approved by
+Added: the audit committee prior to the completion of the audit).
+Added: Exhibit and Financial Statement Schedules
+Added: following documents are filed as part of this Annual Report:
Statement Schedules
−Removed: hereby file as part of this Report the exhibits listed in the attached Exhibit Index.
−Removed: Exhibits which are incorporated herein by reference
−Removed: can be inspected and copied at the public reference facilities maintained by the SEC, 100 F Street, N.E., Room 1580, Washington, D.C.
−Removed: Copies of such material can also be obtained from the Public Reference Section of the SEC, 100 F Street, N.E., Washington, D.C.
+Added: hereby file as part of this Annual report the exhibits listed in the attached Exhibit Index.
+Added: Exhibits which are incorporated herein by
+Added: reference can be inspected and copied at the public reference facilities maintained by the SEC, 100 F Street, N.E., Room 1580, Washington,
+Added: Copies of such material can also be obtained from the Public Reference Section of the SEC, 100 F Street, N.E., Washington,
20549, at prescribed rates or on the SEC website at www.sec.gov.
−Removed: following exhibits are filed with this report.
+Added: following exhibits are filed with this Annual Report.
Exhibits which are incorporated herein by reference can be obtained from the SEC’s
website at http://www.sec.gov.
−Removed: Underwriting Agreement, dated December 1, 2023, by and between the Company and Spartan Capital Securities, LLC (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed by the Registrant on December 6, 2023)
+Added: Underwriting Agreement, dated December 1, 2023, by and between the Registrant and Spartan Capital Securities, LLC (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed by the Registrant on December 6, 2023)
+Added: Business Combination Agreement dated June 19, 2024 (Incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Registrant on June 20, 2024)
Amended and Restated Memorandum and Articles of Association (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Registrant on December 6, 2023)
+Added: Form of Director’s Certificate certifying the special resolution passed by the Registrant at the Extraordinary General Meeting (Incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Registrant on February 7, 2025)
Specimen Unit Certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1/A filed by the Registrant on July 24, 2023)
1 unchanged sentence
Specimen Rights Certificate (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-1/A filed by the Registrant on July 24, 2023)
−Removed: Rights Agreement, dated December 1, 2023, by and between Continental Stock Transfer & Trust Company and the Company (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed by the Registrant on December 6, 2023)
+Added: Rights Agreement, dated December 1, 2023, by and between Continental Stock Transfer & Trust Company and the Registrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed by the Registrant on December 6, 2023)
Description of Securities
−Removed: Letter Agreement, dated December 1, 2023, among the Company and the Company’s officers, directors and Initial Stockholders (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on December 6, 2023)
−Removed: Investment Management Trust Agreement, dated December 1, 2023, by and between Continental Stock Transfer & Trust Company and the Company (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by the Registrant on December 6, 2023)
−Removed: Registration Rights Agreements, dated December 1, 2023, by and between the Company and Initial Stockholders (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed by the Registrant on December 6, 2023)
−Removed: Indemnity Agreements, dated December 1, 2023, by and among the Company and the directors and officers of the Company (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed by the Registrant on December 6, 2023)
−Removed: Subscription Agreement, dated December 1, 2023, by and between the Company and Aimei Investment Ltd.
−Removed: (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed by the Registrant on December 6, 2023)
−Removed: Administrative Service Agreement, dated December 1, 2023, by and between the Company and Aimei Investment Ltd.
−Removed: (incorporated by reference to Exhibit 10.6 to the Current Report on Form 8-K filed by the Registrant on December 6, 2023)
+Added: Letter Agreement, dated December 1, 2023, among the Registrant and the Registrant’s officers, directors and Initial Stockholders (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on December 6, 2023)
+Added: Investment Management Trust Agreement, dated December 1, 2023, by and between Continental Stock Transfer & Trust Company and the Registrant (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by the Registrant on December 6, 2023)
+Added: First Amendment to the Investment Management Trust Agreement, dated February 6, 2025, by and between the Registrant and Continental Stock Transfer & Trust Company (Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on February 7, 2025)
+Added: Registration Rights Agreements, dated December 1, 2023, by and between the Registrant and Initial Stockholders (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed by the Registrant on December 6, 2023)
+Added: Indemnity Agreements, dated December 1, 2023, by and among the Registrant and the directors and officers of the Registrant (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed by the Registrant on December 6, 2023)
+Added: Subscription Agreement, dated December 1, 2023, by and between the Registrant and Aimei Investment Ltd (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed by the Registrant on December 6, 2023)
+Added: Administrative Service Agreement, dated December 1, 2023, by and between the Registrant and Aimei Investment Ltd (incorporated by reference to Exhibit 10.6 to the Current Report on Form 8-K filed by the Registrant on December 6, 2023)
Form of Promissory Note issued to Sponsor (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form S-1/A filed by the Registrant on July 24, 2023)
+Added: Form of Seller Shareholder Support Agreement (Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on June 20, 2024)
+Added: Founder Support Agreement, dated June 19, 2024
+Added: Form of Seller Lock-Up Agreement (Incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed by the Registrant on June 20, 2024)
+Added: Form of Founder Amended and Restated Registration Rights Agreement (Incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed by the Registrant on June 20, 2024)
Form of Code of Ethics (incorporated by reference to Exhibit 14 filed with the Registration Statement on Form S-1/A filed by the Registrant on July 24, 2023)
−Removed: of Subsidiaries
−Removed: Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C.
−Removed: Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C.
−Removed: Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: Clawback Policy
+Added: List of Subsidiaries
+Added: Power of Attorney (included on the signature page to this Annual Report on Form 10-K).
+Added: Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
+Added: Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
+Added: Certification of Principal Executive Officer pursuant to 18 U.S.C.
+Added: 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
+Added: Certification of Principal Financial Officer pursuant to 18 U.S.C.
+Added: 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
+Added: Clawback Policy (incorporated by reference to Exhibit 97.1 to the Annual Report on Form 10-K filed by the Registrant on March 25, 2024)
Audit Committee Charter (incorporated by reference to Exhibit 99.1 to the Registration Statement on Form S-1/A filed by the Registrant on July 24, 2023)
1 unchanged sentence
Nominating Committee Charter (incorporated by reference to Exhibit 99.1 to the Registration Statement on Form S-1/A filed by the Registrant on July 24, 2023)
−Removed: XBRL Instance Document.
−Removed: XBRL Taxonomy Extension Schema Document.
−Removed: XBRL Taxonomy Extension Calculation Linkbase Document.
−Removed: XBRL Taxonomy Extension Definition Linkbase Document.
−Removed: XBRL Taxonomy Extension Label Linkbase Document.
−Removed: XBRL Taxonomy Extension Presentation Linkbase Document.
−Removed: Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
−Removed: to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant caused this report to be signed on its behalf
−Removed: by the undersigned, thereunto duly authorized.
+Added: Inline XBRL Instance Document.
+Added: Inline XBRL Taxonomy Extension
+Added: Schema Document.
+Added: Inline XBRL Taxonomy Extension
+Added: Calculation Linkbase Document.
+Added: Inline XBRL Taxonomy Extension
+Added: Definition Linkbase Document.
+Added: Inline XBRL Taxonomy Extension
+Added: Label Linkbase Document.
+Added: Inline XBRL Taxonomy Extension
+Added: Presentation Linkbase Document.
+Added: Cover Page Interactive
+Added: Data File (formatted as Inline XBRL and contained in Exhibit 101).
+Added: accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No.
+Added: 34-47986, the certifications furnished in Exhibits 32.1
+Added: and 32.2 herewith are deemed to accompany this Form 10-Q and will not be deemed filed for purposes of Section 18 of the Exchange
+Added: Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange
+Added: to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
+Added: on its behalf by the undersigned, thereunto duly authorized.
Health Technology Co., Ltd
March 28, 2025
−Removed: Juan Fernandez Pascual
−Removed: Fernandez Pascual
−Removed: Executive Officer, Secretary and Director
+Added: Executive Officer
+Added: Executive Officer)
+Added: ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Junheng Xie and Heung Ming Wong,
+Added: and each or any one of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for
+Added: him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and
+Added: to file the same, with all exhibits thereto, and other documents in connection therewith, with the United States Securities and Exchange
+Added: Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every
+Added: act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or
+Added: could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or his or her substitutes
+Added: or substitute, may lawfully do or cause to be done by virtue hereof.
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
−Removed: Juan Fernandez Pascual
Executive Officer and Director
−Removed: Fernandez Pascual
Executive Officer)
1 unchanged sentence
Financial Officer and Director
+Added: Heung Ming Wong
Accounting and Financial Officer)
−Removed: Robin Karlsen
HEALTH TECHNOLOGY CO., LTD
−Removed: TO AUDITED FINANCIAL STATEMENTS
+Added: TO FINANCIAL STATEMENTS
Report of Independent Registered Public Accounting Firm (PCAOB ID No:
−Removed: Financial Statements:
−Removed: Balance Sheet as of December 31, 2023
−Removed: Statement of Operations for the period from April 27, 2023 (inception) through December 31, 2023
−Removed: of Changes in Stockholders’ Deficit for the period from April 27, 2023 (inception) through December 31, 2023
−Removed: Statement of Cash Flows for the period from April 27, 2023 (inception) through December 31, 2023
−Removed: to the Financial Statements
+Added: Balance Sheets
+Added: Statements of Operations
+Added: Statements of Changes in Shareholders’ Deficit
+Added: Statements of Cash Flows
+Added: Notes to Financial Statements
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
−Removed: the Stockholders and Board of Directors of
−Removed: Health Technology Co., Ltd.
−Removed: on the Financial Statements
−Removed: have audited the accompanying balance sheet of Aimei Health Technology Co., Ltd.
−Removed: (the “Company”) as of December 31, 2023,
−Removed: and the related statements of operations, changes in stockholders’ deficit, and cash flows for the period from April 27, 2023 (inception)
−Removed: through December 31, 2023, and the related notes (collectively referred to as the “financial statements”).
−Removed: In our opinion,
−Removed: the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and
−Removed: the results of its operations and its cash flows for the period from April 27, 2023 (inception) through December 31, 2023, in conformity
−Removed: with accounting principles generally accepted in the United States of America.
−Removed: Concern Matter
−Removed: accompanying financial statements have been prepared assuming that the Company will continue as a going concern.
−Removed: As discussed in Note
−Removed: 1 to the financial statements, the Company’s business plan is dependent on the completion of a business combination within a prescribed
−Removed: period of time and if not completed will cease all operations except for the purpose of liquidating.
−Removed: The date for mandatory liquidation
−Removed: and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern.
−Removed: plans in regard to these matters are also described in Note 1.
−Removed: The financial statements do not include any adjustments that might result
−Removed: from the outcome of this uncertainty.
−Removed: financial statements are the responsibility of the Company’s management.
−Removed: Our responsibility is to express an opinion on the Company’s
−Removed: financial statements based on our audit.
−Removed: We are a public accounting firm registered with the Public Company Accounting Oversight Board
−Removed: (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S.
−Removed: securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
−Removed: conducted our audit in accordance with the standards of the PCAOB.
−Removed: Those standards require that we plan and perform the audit to obtain
−Removed: reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.
−Removed: is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
−Removed: As part of our audit
−Removed: we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
−Removed: on the effectiveness of the Company’s internal control over financial reporting.
+Added: To the Shareholders and Board of Directors of
+Added: Aimei Health Technology Co., Ltd.
+Added: Opinion on the Financial Statements
+Added: We have audited the accompanying balance
+Added: sheets of Aimei Health Technology Co., Ltd.
+Added: (the “Company”) as of December 31, 2024 and 2023, and the related statements of
+Added: operations, changes in shareholders’ deficit, and cash flows for the year ended December 31, 2024, and for the period from April
+Added: 27, 2023 (inception) through December 31, 2023 , and the related notes (collectively referred to as the “financial statements”).
+Added: In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
+Added: 31, 2024 and December 31, 203, and the results of its operations and its cash flows for the year ended December 31, 2024, and for the
+Added: period from April 27, 2023 (inception) through December 31, 2023, in conformity with accounting principles generally accepted in the United
+Added: States of America.
+Added: Going Concern Matter
+Added: The accompanying financial statements have
+Added: been prepared assuming that the Company will continue as a going concern.
+Added: As discussed in Note 1 to the financial statements, the Company’s
+Added: business plan is dependent on the completion of a business combination within a prescribed period of time and if not completed will cease
+Added: all operations except for the purpose of liquidating.
+Added: The date for mandatory liquidation and subsequent dissolution raises substantial
+Added: doubt about the Company’s ability to continue as a going concern.
+Added: Management’s plans in regard to these matters are also described
+Added: The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
+Added: Basis for Opinion
+Added: These financial statements are the responsibility
+Added: of the Company’s management.
+Added: Our responsibility is to express an opinion on the Company’s financial statements based on our
+Added: We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”)
+Added: and are required to be independent with respect to the Company in accordance with the U.S.
+Added: federal securities laws and the applicable
+Added: rules and regulations of the Securities and Exchange Commission and the PCAOB.
+Added: We conducted our audits in accordance with
+Added: the standards of the PCAOB.
+Added: Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
+Added: financial statements are free of material misstatement, whether due to error or fraud.
+Added: The Company is not required to have, nor were we
+Added: engaged to perform, an audit of its internal control over financial reporting.
+Added: As part of our audits we are required to obtain an understanding
+Added: of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s
+Added: internal control over financial reporting.
Accordingly, we express no such opinion.
−Removed: audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
−Removed: fraud, and performing procedures that respond to those risks.
−Removed: Such procedures included examining, on a test basis, evidence regarding
−Removed: the amounts and disclosures in the financial statements.
−Removed: Our audit also included evaluating the accounting principles used and significant
−Removed: estimates made by management, as well as evaluating the overall presentation of the financial statements.
−Removed: We believe that our audit provides
−Removed: a reasonable basis for our opinion.
−Removed: MaloneBailey, LLP
+Added: Our audits included performing procedures
+Added: to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that
+Added: respond to those risks.
+Added: Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
+Added: Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as
+Added: evaluating the overall presentation of the financial statements.
+Added: We believe that our audits provide a reasonable basis for our opinion.
+Added: /s/ MaloneBailey, LLP
www.malonebailey.com
−Removed: have served as the Company’s auditor since 2023.
+Added: We have served as the Company’s auditor
+Added: Houston, Texas
+Added: March 28, 2025
HEALTH TECHNOLOGY CO., LTD
−Removed: December 31, 2023
+Added: Current assets:
+Added: Prepaid expenses
Total current assets
−Removed: Cash and marketable securities held in Trust Account
−Removed: Liabilities and Stockholders’ Deficit
+Added: Cash held in Trust Account
+Added: TEMPORARY EQUITY AND SHAREHOLDERS’ DEFICIT
Current liabilities:
−Removed: Accrued expenses
+Added: loan – related party
+Added: Due to a related company
Total current liabilities
−Removed: Deferred underwriter fee payable
+Added: Deferred underwriter
TOTAL LIABILITIES
Commitments and contingencies (Note 7)
−Removed: Redeemable Ordinary share
−Removed: Redeemable Ordinary share, $ 0.0001 par value;
−Removed: 500,000,000 shares authorized;
−Removed: 6,900,000 shares issued and outstanding subject to possible redemption, at redemption value of $ 10.13
−Removed: Stockholders’ Deficit
−Removed: Ordinary share, $ 0.0001 par value;
+Added: Ordinary shares, subject
+Added: to possible redemption.
+Added: 6,900,000 and 6,900,000 shares issued and outstanding at redemption value of $ 10.69 and $ 10.13 as of December
+Added: 31, 2024 and 2023, respectively
+Added: Shareholders’ deficit:
+Added: Ordinary shares, $ 0.0001
500,000,000 shares authorized;
−Removed: 2,126,000 issued and outstanding (excluding 6,900,000 shares subject to possible redemption)
−Removed: Additional paid-in capital
+Added: 2,126,000 and 2,126,000 shares issued and outstanding as of December 31, 2024 and 2023,
+Added: respectively (excluding 6,900,000 and 6,900,000 shares subject to possible redemption, respectively)
Accumulated deficit
−Removed: Total Stockholders’ Deficit
−Removed: Total Liabilities, Redeemable Ordinary share and Stockholders’ Deficit
+Added: ( 1,476,823 )
+Added: Total shareholders’ deficit
+Added: ( 1,476,610 )
+Added: LIABILITIES, TEMPORARY EQUITY AND SHAREHOLDERS’ DEFICIT
accompanying notes are an integral part of these financial statements.
1 unchanged sentence
OF OPERATIONS
−Removed: For the period from April 27, 2023 (inception) through
−Removed: December 31, 2023
−Removed: Formation and operating costs
−Removed: Loss from operations
−Removed: Other income:
−Removed: Interest earned on investments held in trust
−Removed: Total other income
−Removed: Weighted average shares outstanding, basic and diluted
−Removed: Basic and diluted net income per share
+Added: ended December 31,
+Added: the period from April 27, 2023 (inception) through December 31,
+Added: and operating costs
+Added: $ ( 1,064,786 )
+Added: from operations
+Added: ( 1,064,786 )
+Added: earned on assets held in trust
+Added: and diluted weighted average shares outstanding, ordinary shares subject to possible redemption
+Added: and diluted net income per ordinary shares subject to possible redemption
+Added: and diluted weighted average shares outstanding, ordinary shares attributable to not subject to possible redemption
+Added: and diluted net income per share, ordinary shares attributable to not subject to possible redemption
accompanying notes are an integral part of these financial statements.
HEALTH TECHNOLOGY CO., LTD
−Removed: OF CHANGES IN STOCKHOLDERS’ DEFICIT
−Removed: THE PERIOD FROM APRIL 27, 2023 (INCEPTION) THROUGH DECEMBER 31, 2023
−Removed: Ordinary shares
+Added: OF CHANGES IN SHAREHOLDERS’ DEFICIT
+Added: Ended December 31, 2024
Stockholders’
+Added: as of December 31, 2023
+Added: $ ( 134,337 )
+Added: $ ( 134,124 )
+Added: funds attributable to common stock subject to redemption
+Added: Remeasurement
+Added: of ordinary shares subject to possible redemption
+Added: ( 3,617,001 )
+Added: ( 3,617,001 )
+Added: as of December 31, 2024
+Added: $ ( 1,476,823 )
+Added: $ ( 1,476,610 )
+Added: The Period From April 27, 2023 (Inception) to December 31, 2023
+Added: Stockholders’
Balance – April 27, 2023 (inception)
Issuance of Founder Shares to Sponsor
−Removed: Sale of public units through public offering
−Removed: Sale of Private Placement Units
−Removed: Offering costs
+Added: of public units through public offering
+Added: of Private Placement Units
( 2,070,665 )
( 2,070,665 )
−Removed: Deferred underwriting costs
−Removed: Issuance of representative shares
−Removed: Common shares subject to redemption
+Added: underwriting costs
+Added: of representative shares
+Added: shares subject to redemption
( 6,900,000 )
1 unchanged sentence
( 69,690,000 )
−Removed: Remeasurement of common stock subject to possible redemption
−Removed: Accretion of additional paid in capital to accumulated deficit
−Removed: Balance – December 31, 2023
+Added: Remeasurement
+Added: of ordinary shares subject to possible redemption
+Added: of additional paid in capital to accumulated deficit
+Added: – December 31, 2023
$ ( 134,337 )
$ ( 134,124 )
+Added: $ ( 134,337 )
+Added: $ ( 134,124 )
accompanying notes are an integral part of these financial statements.
1 unchanged sentence
OF CASH FLOWS
−Removed: For the Period from
−Removed: April 27, 2023
−Removed: (inception) through
−Removed: December 31, 2023
−Removed: Cash flow from operating activities:
−Removed: Adjustments to reconcile net income to net cash used in operating activities:
−Removed: Interest earned on investments held in trust
−Removed: Formation and operating costs paid by Sponsor
−Removed: Changes in operating assets and liabilities:
+Added: Period from April 27, 2023
+Added: Ended December 31, 2024
+Added: through December 31, 2023
+Added: Cash flows from operating
+Added: Adjustments to reconcile net income to net
+Added: cash used in operating activities:
+Added: Interest earned in assets held in trust
+Added: ( 3,617,001 )
+Added: Change in operating assets and liabilities:
+Added: Formation costs paid by Sponsor under Promissory
+Added: Note – Related Party
+Added: Prepaid expenses
+Added: Due to a related company
Accrued expenses
−Removed: Net cash used in operating activities
−Removed: Cash flows from investing activities:
−Removed: Investment of cash in Trust Account
+Added: Net cash used in operating
+Added: Cash flows from investing
+Added: Extension payments deposited in Trust Account
+Added: Investment of cash in
+Added: Trust Account
( 69,690,000 )
−Removed: Net cash used in investing activities
+Added: Net cash used in investing
( 69,690,000 )
−Removed: Cash flow from financing activities:
−Removed: Proceeds from issuance of founder shares to Sponsor
−Removed: Proceeds from sale of units through public offering
+Added: Cash flows from financing
+Added: Proceeds from issuance of ordinary shares to
+Added: Proceeds from sale of units through public
Proceeds from sale of private placement units
Proceeds from promissory note – related
+Added: Proceeds from extension promissory note –
+Added: related party
+Added: Advance from related party
Payment of offering costs
( 2,070,665 )
−Removed: Repayment of promissory note - related party
−Removed: Net cash provided by financing activities
+Added: Repayment of promissory
+Added: note – related party
+Added: Net cash provided by financing
NET CHANGE IN CASH
−Removed: Cash at the beginning of the period
−Removed: Cash at the end of the period
−Removed: Supplemental disclosure of non-cash financing activities:
−Removed: Deferred underwriting fee payable
−Removed: Initial classification of shares subject to redemption
−Removed: Subsequent remeasurement to redemption value- interest income
+Added: CASH, BEGINNING OF PERIOD
+Added: CASH, END OF PERIOD
+Added: Non-cash investing and financing
+Added: Deferred underwriting
+Added: Initial classification
+Added: of shares subject to redemption
+Added: Remeasurement of ordinary
+Added: stock subject to possible redemption
+Added: Extension funds attributable
+Added: to common stock subject to redemption
Issuance of representative shares
−Removed: Accretion of additional paid in capital to accumulated deficit
+Added: Accretion of additional
+Added: paid-in capital to accumulated deficit
accompanying notes are an integral part of these financial statements.
1 unchanged sentence
TO FINANCIAL STATEMENTS
−Removed: DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS
−Removed: Health Technology Co., Ltd (the “Company”) is a blank check company incorporated in the Cayman Islands on April 27, 2023 .
+Added: 1 - ORGANIZATION AND BUSINESS BACKGROUND
+Added: Health Technology Co., Ltd.
+Added: (the “Company”) is a blank check company incorporated in the Cayman Islands on April 27, 2023 .
The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization,
−Removed: reorganization or similar business combination with one or more businesses or entities (“Business Combination”).
−Removed: there is no restriction or limitation on what industry its target operates in, it is the Company’s intention to pursue prospective
−Removed: targets that are focused on healthcare innovation.
−Removed: The Company anticipates targeting what are traditionally known as “small cap”
−Removed: companies domiciled in North America, Europe and/or the Asia Pacific (“APAC”) regions that are developing assets in the biopharmaceutical,
−Removed: medical technology/medical device and diagnostics space which aligns with its management team’s experience in operating health
−Removed: care companies and in drug and device technology development as well as diagnostic and other services.
−Removed: 31 , 2023, the Company had not yet commenced any operations.
−Removed: All activity through December
−Removed: 31 , 2023 related to the Company’s formation and the Initial Public Offering (as
−Removed: defined below) .
−Removed: The Company will not generate any operating revenues until after the completion of its initial Business
−Removed: Combination, at the earliest.
−Removed: The Company will generate non-operating income in the form of interest income on cash in bank and
−Removed: investments held in trust account from the proceeds derived from the Initial Public Offering.
−Removed: The Company has selected December 31
−Removed: as its fiscal year end.
−Removed: The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the
−Removed: risks associated with early stage and emerging growth companies.
+Added: reorganization or similar business combination with one or more businesses or entities.
+Added: Although there is no restriction or limitation
+Added: on what industry its target operates in, it is the Company’s intention to pursue prospective targets that are focused on healthcare
+Added: The Company anticipates targeting what are traditionally known as “small cap” companies domiciled in North America,
+Added: Europe and/or the Asia Pacific regions that are developing assets in the biopharmaceutical, medical technology/medical device and diagnostics
+Added: space which aligns with its management team’s experience in operating health care companies and in drug and device technology development
+Added: as well as diagnostic and other services.
+Added: of December 31, 2024, the Company had not yet commenced any operations.
+Added: All activities through December 31, 2024 related to the Company’s
+Added: formation and the Initial Public Offering (as defined below).
+Added: Since the Initial Public Offering, the Company’s activity has been
+Added: limited to the evaluation of business combination candidates.
+Added: The Company will not generate any operating revenue until after the completion
+Added: of its initial business combination, at the earliest.
+Added: The Company will generate non-operating income in the form of interest income on
+Added: cash in bank and assets held in the Trust Account (as defined below) from the proceeds derived from the Initial Public Offering.
+Added: Company has selected December 31 as its fiscal year end.
+Added: The Company is an early stage and emerging growth company and, as such, the
+Added: Company is subject to all of the risks associated with early stage and emerging growth companies.
Company’s sponsor is Aimei Investment Ltd, a Cayman Islands exempted company (the “Sponsor”).
−Removed: The registration
−Removed: statement for the Company’s Initial Public Offering was declared effective on November 30, 2023.
−Removed: On December 6, 2023, the
−Removed: Company consummated its Initial Public Offering of 6,900,000
−Removed: units (the “Units” and, with respect to the shares of Ordinary share included in the Units being offered, the
−Removed: “Public Shares”), at $ 10.00
−Removed: per Unit, which includes full exercise of the underwriter’s over-allotment option of 900,000
−Removed: Units, generating gross proceeds of $ 69,000,000 (the
−Removed: “Initial Public Offering”), and incurring offering costs of $ 2,070,665 and
−Removed: for deferred underwriting commissions (see Note 5).
−Removed: The Company granted the underwriter a 45-day option to purchase up to an
−Removed: additional 900,000
−Removed: Units at the Initial Public Offering price to cover over-allotments, if any.
−Removed: On December 6, 2023, the over-allotment option was
−Removed: exercised in full.
+Added: The registration statement
+Added: for the Company’s Initial Public Offering was declared effective on November 30, 2023.
+Added: On December 6, 2023, the Company consummated
+Added: its Initial Public Offering of 6,900,000 units (the “Units” and, with respect to the ordinary shares included in the Units
+Added: being offered, the “Public Shares”), at $ 10.00 per Unit, which includes full exercise of the underwriters’ over-allotment
+Added: option of 900,000 Units, generating gross proceeds of $ 69,000,000 (the “Initial Public Offering”), and incurring offering
+Added: costs of $ 2,070,665 and $ 690,000 for deferred underwriting commissions (see Note 7).
+Added: The Company granted the underwriters a 45-day option
+Added: to purchase up to an additional 900,000 Units at the Initial Public Offering price to cover over-allotments, if any.
+Added: On December 6, 2023,
+Added: the over-allotment option was exercised in full.
Simultaneously
4 unchanged sentences
sale of the Units in the Initial Public Offering and a portion of the proceeds from the sale of the Private Units was placed in a trust
−Removed: account (the “Trust Account”), located in the United States and held as cash items or may be invested only in only in U.S.
−Removed: government treasury bills, notes and bonds with a maturity of 185 days or less or in money market funds meeting certain conditions under
−Removed: Rule 2a-7 under the Investment Company Act and which invest solely in U.S.
−Removed: Treasuries, as determined by the Company, until the earlier
−Removed: (i) the consummation of a Business Combination, or (ii) the distribution of the funds in the Trust Account to the Company’s
−Removed: shareholders, as described below.
+Added: account (the “Trust Account”), located in the United States and held as cash items or may be invested only in U.S.
+Added: treasury bills, notes and bonds with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7
+Added: under the Investment Company Act and which invest solely in U.S.
+Added: Treasuries, as determined by the Company, until the earlier of:
+Added: the consummation of a business combination, or (ii) the distribution of the funds in the Trust Account to the Company’s shareholders,
+Added: as described below.
Company will provide its public shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion
−Removed: of our initial business combination either (i) in connection with a shareholder meeting called to approve the initial business combination
+Added: of its initial business combination either (i) in connection with a shareholder meeting called to approve the initial business combination
or (ii) by means of a tender offer.
2 unchanged sentences
they vote for the business combination.
−Removed: If a vote is held to approve an initial business combination will consummate such initial business
−Removed: combination only if the Company has the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of
+Added: If a vote is held to approve such an initial business combination, the Company will consummate
+Added: such initial business combination only if the Company has the affirmative vote of a majority of the shareholders who attend and vote
+Added: at a general meeting of the Company.
shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially
5 unchanged sentences
of a business combination with respect to the Company’s rights.
+Added: HEALTH TECHNOLOGY CO., LTD
+Added: TO FINANCIAL STATEMENTS
a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other reasons, the Company
will, pursuant to its amended and restated memorandum and articles of association, conduct the redemptions pursuant to Rule 13e-4 and
−Removed: Regulation 14E of the Exchange Act, which regulate issuer tender offers, and file tender offer documents with the SEC prior to completing
−Removed: our initial business combination which contain substantially the same financial and other information about the initial business combination
−Removed: as is required under the SEC’s proxy rules.
+Added: Regulation 14E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which regulate issuer tender offers,
+Added: and file tender offer documents with the U.S.
+Added: Securities and Exchange Commission (the “SEC”) prior to completing its initial
+Added: business combination which contain substantially the same financial and other information about the initial business combination as is
+Added: required under the SEC’s proxy rules.
Sponsor has agreed (i) to vote any shares owned by them in favor of any proposed business combination, (ii) not to redeem any shares
−Removed: in connection with a shareholder vote to approve a proposed initial business combination or any amendment to our charter prior to the
−Removed: consummation of our initial business combination and (iii) not to sell any shares to us in a tender offer in connection with any proposed
−Removed: business combination.
−Removed: However, the Sponsor will be entitled to liquidating distributions from the Trust Account with respect to any Public
−Removed: Shares purchased during or after the Initial Public Offering if the Company fails to complete its Business Combination.
−Removed: Company will have until 12 months from the closing of the Initial Public Offering (or up to 24 months from the closing of the IPO if
−Removed: the Company extends the period of time to consummate a Business Combination by up to 12 additional months through 12 one-month extensions
−Removed: of time, as further provided in the Company’s amended and restated memorandum and articles of association) to consummate a Business
−Removed: Combination (the “Combination Period”).
−Removed: If the Company is unable to complete a Business Combination within the Combination
−Removed: Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not
−Removed: more than five business days thereafter, redeem 100% of the outstanding public shares which redemption will completely extinguish public
−Removed: shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable
−Removed: law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining holders of ordinary
−Removed: shares and our board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the company, subject
−Removed: (in the case of (ii) and (iii) above) to its obligations to provide for claims of creditors and the requirements of applicable law .
−Removed: underwriter has agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company
+Added: in connection with a shareholder vote to approve a proposed initial business combination or any amendment to the Company’s charter
+Added: prior to the consummation of its initial business combination and (iii) not to sell any shares to the Company in a tender offer in connection
+Added: with any proposed business combination.
+Added: However, the Sponsor will be entitled to liquidating distributions from the Trust Account with
+Added: respect to any Public Shares purchased during or after the Initial Public Offering if the Company fails to complete its business combination.
+Added: Company initially had 12 months from the closing of the Initial Public Offering (or up to 24 months from the closing of the Initial Public
+Added: Offering if the Company extends the period of time to consummate a business combination by up to 12 additional months through 12 one-month
+Added: extensions of time, as further provided in the Company’s amended and restated memorandum and articles of association) to consummate
+Added: a business combination (the “Combination Period”).
+Added: If the Company is unable to complete a business combination within the
+Added: Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible
+Added: but not more than five business days thereafter, redeem 100% of the outstanding Public Shares which redemption will completely extinguish
+Added: public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject
+Added: to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s
+Added: remaining holders of ordinary shares and its board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution
+Added: of the Company, subject (in the case of (ii) and (iii) above) to its obligations to provide for claims of creditors and the requirements
+Added: of applicable law.
+Added: underwriters have agreed to waive their rights to the deferred underwriting commission held in the Trust Account in the event the Company
does not complete a business combination within the Combination Period and, in such event, such amounts will be included with the funds
6 unchanged sentences
in full), except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and
−Removed: except as to any claims under its indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the
−Removed: Securities Act.
−Removed: In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible
−Removed: to the extent of any liability for such third party claims.
−Removed: The Company has not independently verified whether our sponsor has sufficient
−Removed: funds to satisfy its indemnity obligations and believe that the Sponsor’s only assets are securities of the Company.
−Removed: has not asked the Sponsor to reserve for such obligations and therefore believe the Sponsor will be unlikely to satisfy its indemnification
−Removed: obligations if it is required to do so.
−Removed: However, the Company believes the likelihood of our sponsor having to indemnify the trust account
−Removed: is limited because the Company will endeavor to have all vendors and prospective target businesses as well as other entities execute
−Removed: agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the trust account.
+Added: except as to any claims under its indemnity of the underwriters of the Initial Public Offering against certain liabilities, including
+Added: liabilities under the Securities Act.
+Added: In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor
+Added: will not be responsible to the extent of any liability for such third-party claims.
+Added: The Company has not independently verified whether
+Added: the Sponsor has sufficient funds to satisfy its indemnity obligations and believes that the Sponsor’s only assets are securities
+Added: of the Company.
+Added: The Company has not asked the Sponsor to reserve for such obligations and therefore believes the Sponsor will be unlikely
+Added: to satisfy its indemnification obligations if it is required to do so.
+Added: However, the Company believes the likelihood of the Sponsor having
+Added: to indemnify the Trust Account is limited because the Company will endeavor to have all vendors and prospective target businesses as
+Added: well as other entities execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held
+Added: in the Trust Account.
+Added: June 19, 2024, the Company entered into a definitive Business Combination Agreement (the “Merger Agreement”) for a business
+Added: combination with (i) United Hydrogen Group Inc., an exempted company incorporated with limited liability in the Cayman Islands (“United
+Added: Hydrogen”), (ii) United Hydrogen Global Inc., an exempted company incorporated with limited liability in the Cayman Islands (“Pubco”),
+Added: (iii) United Hydrogen Victor Limited, an exempted company incorporated with limited liability in the Cayman Islands and a wholly-owned
+Added: subsidiary of Pubco (“First Merger Sub”);
+Added: (iv) United Hydrogen Worldwide Limited, an exempted company incorporated with limited
+Added: liability in the Cayman Islands and a wholly-owned subsidiary of Pubco (“Second Merger Sub” and, together with Pubco and
+Added: First Merger Sub, each, individually, an “Acquisition Entity” and, collectively, the “Acquisition Entities”);
+Added: and (v) Aimei Investment Ltd., a Cayman Islands exempted company, in the capacity as, from and after the closing of the transactions
+Added: contemplated by the Merger Agreement (the “Closing”), the representative for the Company and its shareholders (the “Sponsor”).
+Added: HEALTH TECHNOLOGY CO., LTD
+Added: TO FINANCIAL STATEMENTS
+Added: to the Merger Agreement, subject to the terms and conditions set forth therein, (i) First Merger Sub will merge with and into the United
+Added: Hydrogen (the “First Merger”), whereby the separate existence of First Merger Sub will cease, and United Hydrogen will be
+Added: the surviving corporation of the First Merger and become a wholly-owned subsidiary of Pubco;
+Added: and (ii) following confirmation of the effective
+Added: filing of the First Merger, and as part of the same overall transaction as the First Merger, Second Merger Sub will merge with and into
+Added: the Company (the “Second Merger”, and together with the First Merger, the “Mergers”), whereby the separate existence
+Added: of Second Merger Sub will cease, and the Company will be the surviving corporation of the Second Merger as a wholly-owned subsidiary
+Added: February 6, 2025, the Company entered into an amendment (the “Trust Agreement Amendment”) to the Investment Management Trust
+Added: Agreement with Continental Stock Transfer & Trusts Company (“Trustee”).
+Added: Pursuant to the Trust Agreement Amendment, the
+Added: amount of funds to be deposited into the trust account managed by the Trustee (the “Trust Account”) in connection with extending
+Added: the timeframe within which the Company must consummate its initial business combination (“Extension”), is adjusted from $ 0.033
+Added: per each share sold in its IPO (the “Public Share”) (for each monthly extension) to an amount equal to $ 150,000 for all outstanding
+Added: Public Shares (for each monthly extension).
+Added: of the date of this report, the Company has extended four times by an additional one month each time, and so it now has until April 6,
+Added: 2025 to consummate a business combination.
+Added: Pursuant to the terms of the current amended and restated memorandum and articles of association
+Added: and the trust agreement between the Company and Continental Stock Transfer & Trust Company, LLC, in order to extend the time available
+Added: for the Company to consummate its initial business combination, the Company’s insiders or their affiliates or designees, must deposit
+Added: into the Trust Account $ 150,000 on or prior to the date of the applicable deadline.
+Added: On each of December 11, 2024 and January 13, 2025,
+Added: the Company has deposited $ 227,700 into the Trust Account in order to extend the amount of available time to complete a business combination
+Added: until February 6, 2025.
+Added: On each of February 6, 2025 and March 6, 2025, the Company has deposited in an amount of $ 150,000 into the Trust
+Added: Account in order to extend the amount of available time to complete a business combination until April 6, 2025.
and Capital Resources
−Removed: of December 31, 2023, the Company had $ 580,717 in its operating bank account, $ 69,889,848 in its trust account, and working capital of
−Removed: approximately $ 555,876 .
−Removed: Company’s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the payment of $ 25,000
−Removed: from the Sponsor to cover for certain offering costs on the Company’s behalf in exchange for issuance of Founder Shares (as defined
−Removed: in Note 5), and loan from the Sponsor of approximately $ 210,151 under the Note (as defined in Note
−Removed: The Company has repaid the note in full on December 7, 2023.
−Removed: Subsequent to the consummation of the Initial Public Offering,
−Removed: the Company’s liquidity has been satisfied through the net proceeds from the consummation of the Initial Public Offering and the
−Removed: Private Placement held outside of the Trust Account.
−Removed: In addition, in order to finance transaction costs in connection with a Business
−Removed: Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated
−Removed: to, provide the Company Working Capital Loans (as defined in Note 5).
−Removed: As of December 31, 2023, there were no amounts outstanding under
−Removed: any Working Capital Loan.
−Removed: Over the period of time to complete a business combination, the Company will
−Removed: be using the funds held outside of the Trust Account for paying existing accounts payable, identifying and evaluating prospective initial
−Removed: Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting
−Removed: the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination.
+Added: of December 31, 2024, the Company had $ 28,208 in its bank account, $ 73,784,549 in its Trust Account and working capital deficit of $ 747,377 .
+Added: Company’s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through (i) the payment of $ 25,000
+Added: from the Sponsor to cover certain offering costs on the Company’s behalf in exchange for issuance of Founder Shares (see Note 5),
+Added: and (ii) a loan from the Sponsor of approximately $ 210,151 under the Note (as defined in Note 5).
+Added: The Company has repaid the note in
+Added: full on December 7, 2023.
+Added: Subsequent to the consummation of the Initial Public Offering, the Company’s liquidity has been satisfied
+Added: through the net proceeds from the consummation of the Initial Public Offering and the Private Placement held outside of the Trust Account.
+Added: In addition, in order to finance transaction costs in connection with a business combination, the Sponsor or an affiliate of the Sponsor,
+Added: or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (as
+Added: defined in Note 5).
+Added: As of December 31, 2024, there were no amounts outstanding under any Working Capital Loan.
+Added: the period of time to complete a business combination, the Company will be using the funds held outside of the Trust Account for paying
+Added: existing accounts payable, identifying and evaluating prospective initial business combination candidates, performing due diligence on
+Added: prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring,
+Added: negotiating and consummating the business combination.
+Added: HEALTH TECHNOLOGY CO., LTD
+Added: TO FINANCIAL STATEMENTS
Concern Consideration
connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”)
−Removed: 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined
−Removed: that if the Company is unsuccessful in consummating an initial business combination within the prescribed period of time from the closing
−Removed: of the IPO, the requirement that the Company cease all operations, redeem the public shares and thereafter liquidate and dissolve raises
−Removed: substantial doubt about the ability to continue as a going concern.
−Removed: The financial statements do not include any adjustments that might
−Removed: result from the outcome of this uncertainty.
−Removed: The accompanying financial statements have been prepared in conformity
−Removed: with generally accepted accounting principles in the United States of America (“GAAP”), which contemplate continuation of
−Removed: the Company as a going concern.
−Removed: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
+Added: 2014-15, “ Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern ,” management
+Added: has determined that if the Company is unsuccessful in consummating an initial business combination within the prescribed period of time
+Added: from the closing of the Initial Public Offering, the requirement that the Company cease all operations, redeem the Public Shares and
+Added: thereafter liquidate and dissolve raises substantial doubt about the ability to continue as a going concern.
+Added: The financial statements
+Added: do not include any adjustments that might result from the outcome of this uncertainty.
+Added: The accompanying financial statements have been
+Added: prepared in conformity with generally accepted accounting principles in the U.S.
+Added: GAAP”), which contemplate continuation
+Added: of the Company as a going concern.
+Added: 2 – SIGNIFICANT ACCOUNTING POLICIES
of presentation
−Removed: accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America
+Added: accompanying financial statements have been prepared in accordance with U.S.
GAAP and pursuant to the rules and regulations of the SEC.
17 unchanged sentences
extended transition period difficult or impossible because of the potential differences in accounting standards used.
−Removed: preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
−Removed: amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
−Removed: reported amounts of revenues and expenses during the reporting period.
+Added: preparation of financial statements in conformity with U.S.
+Added: GAAP requires management to make estimates and assumptions that affect the
+Added: reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements
+Added: and the reported amounts of expenses during the reporting period.
estimates requires management to exercise significant judgment.
It is at least reasonably possible that the estimate of the effect of
−Removed: a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating
−Removed: its estimate, could change in the near term due to one or more future confirming events.
−Removed: Accordingly, the actual results could differ
−Removed: significantly from those estimates.
+Added: a condition, situation or set of circumstances that existed as of the date of the financial statements, which management considered in
+Added: formulating its estimate, could change in the near term due to one or more future confirming events.
+Added: Accordingly, the actual results
+Added: could differ significantly from those estimates.
+Added: HEALTH TECHNOLOGY CO., LTD
+Added: TO FINANCIAL STATEMENTS
and cash equivalents
Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents.
−Removed: The Company had $ 580,717 in cash and no cash equivalents as of December 31, 2023.
−Removed: Cash and marketable securities held in trust account
−Removed: of December 31, 2023, substantially all of the assets held in the Trust Account were held in U.S.
−Removed: Treasury Securities Money Market Funds.
−Removed: All of the Company’s investments held in the Trust Account are classified as trading securities.
−Removed: Trading securities are presented
−Removed: on the balance sheet at fair value at the end of each reporting period.
−Removed: Gains and losses resulting from the change in fair value of investments
−Removed: held in Trust Account are included in investment income earned on investments held in Trust in the accompanying statement of operations.
−Removed: The estimated fair values of investments held in Trust Account are determined using available market information.
−Removed: As of December 31,
−Removed: 2023, the estimated fair values of investments held in Trust Account was $ 69,889,848 .
−Removed: Costs Associated with the Initial Public Offering
−Removed: costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly
−Removed: related to the Initial Public Offering.
−Removed: These costs, together with the cash underwriter fee of $ 1,380,000 and deferred underwriting fee
−Removed: of $ 690,000 , were charged to additional paid-in capital upon completion of the Initial Public Offering.
−Removed: share Subject to Possible Redemption
−Removed: of the 6,900,000 shares of Ordinary share sold as part of the Units in the Initial Public Offering contain a redemption feature which
−Removed: allows for the redemption of such Public Shares in connection with the Company’s liquidation, if there is a stockholder vote or
−Removed: tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s amended and
−Removed: restated certificate of incorporation.
−Removed: In accordance with ASC 480, conditionally redeemable Ordinary share (including shares of Ordinary
−Removed: share that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of
−Removed: uncertain events not solely within the Company’s control) are classified as temporary equity.
−Removed: Ordinary liquidation events, which
−Removed: involve the redemption and liquidation of all of the entity’s equity instruments, are excluded from the provisions of ASC 480.
−Removed: Although the Company did not specify a maximum redemption threshold, its charter provides that currently, the Company will not redeem
−Removed: its Public Shares in an amount that would cause its net tangible assets (stockholders’ equity) to be less than $ 5,000,001 .
−Removed: the threshold in its charter would not change the nature of the underlying shares as redeemable and thus Public Shares would be required
−Removed: to be disclosed outside of permanent equity.
−Removed: Accordingly, on December 31, 2023, 6,900,000 shares of Ordinary share subject to possible
−Removed: redemption at the redemption amount were presented at redemption value as temporary equity, outside of the stockholders’ deficit
−Removed: section of the Company’s balance sheet.
−Removed: Company complies with the accounting and reporting requirements of ASC Topic 740, “Income Taxes,” which requires an asset
−Removed: and liability approach to financial accounting and reporting for income taxes.
−Removed: Deferred income tax assets and liabilities are computed
−Removed: for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible
−Removed: amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income.
−Removed: Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
−Removed: Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax
−Removed: positions taken or expected to be taken in a tax return.
−Removed: For those benefits to be recognized, a tax position must be more-likely-than-not
−Removed: to be sustained upon examination by taxing authorities.
+Added: The Company did no t have any cash equivalents as of December 31, 2024 and 2023.
+Added: As of December 31, 2024 and 2023, the cash balance was
+Added: $ 28,208 and $ 580,717 , respectively.
+Added: held in trust account
+Added: July 16, 2024, the Company instructed their trust custodian to liquidate their positions in marketable securities and invest 100% of
+Added: the trust account in an interest-bearing demand deposit account.
+Added: As of December 31, 2024, all the assets held in the Trust Account were
+Added: held in an interest-bearing demand deposit account.
+Added: As of December 31, 2023, substantially all the assets held in the Trust Account were
+Added: Treasury Bills.
+Added: The Company accounts for its marketable securities under ASC 320, where securities are presented at fair
+Added: value on the balance sheets and with gains or losses, if any, presented on the statements of operations.
+Added: As of December 31, 2024 and
+Added: 2023, the assets held in Trust Account was $ 73,784,549 and $ 69,889,848 , respectively.
+Added: shares subject to possible redemption
+Added: of the 6,900,000 ordinary shares sold as part of the Units in the Initial Public Offering contain a redemption feature which allows for
+Added: the redemption of such Public Shares in connection with the Company’s liquidation, if there is a shareholder vote or tender offer
+Added: in connection with the Business Combination and in connection with certain amendments to the Company’s amended and restated certificate
+Added: of incorporation.
+Added: In accordance with Accounting Standards Codification (“ASC”) 480 “ Distinguishing Liabilities from
+Added: Equity ”, conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either
+Added: within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s
+Added: control) are classified as temporary equity.
+Added: Ordinary liquidation events, which involve the redemption and liquidation of all of the
+Added: entity’s equity instruments, are excluded from the provisions of ASC 480.
+Added: Although the Company did not specify a maximum redemption
+Added: threshold, its charter provides that currently, the Company will not redeem its Public Shares in an amount that would cause its net tangible
+Added: assets (shareholders’ equity) to be less than $ 5,000,001 .
+Added: However, the threshold in its charter would not change the nature of
+Added: the underlying shares as redeemable and thus Public Shares would be required to be disclosed outside of permanent equity.
+Added: as of December 31, 2024 and 2023, 6,900,000 and 6,900,000 ordinary shares subject to possible redemption at the redemption amount, respectively,
+Added: were presented at redemption value as temporary equity, outside of the shareholders’ deficit section of the Company’s balance
+Added: Company complies with the accounting and reporting requirements of ASC Topic 740, “ Income Taxes ,” (“ASC 740”)
+Added: which requires an asset and liability approach to financial accounting and reporting for income taxes.
+Added: Deferred income tax assets and
+Added: liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in
+Added: future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected
+Added: to affect taxable income.
+Added: Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected
+Added: to be realized.
+Added: 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions
+Added: taken or expected to be taken in a tax return.
+Added: For those benefits to be recognized, a tax position must be more-likely-than-not to be
+Added: sustained upon examination by taxing authorities.
The Company’s management determined that the Cayman Islands is the Company’s
1 unchanged sentence
The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income
−Removed: There were no unrecognized tax benefits as of December 31, 2023 and no amounts accrued for interest and penalties.
−Removed: is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its
+Added: There were no unrecognized tax benefits as of December 31, 2024 and 2023 and no amounts were accrued for interest and penalties
+Added: during the years ended December 31, 2024 and 2023.
+Added: The Company is currently not aware of any issues under review that could result in
+Added: significant payments, accruals or material deviation from its position.
Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently
not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States.
−Removed: As such, there is no provision for
−Removed: income taxes for the period from April 27, 2023 (inception) to December 31, 2023.
−Removed: Income (loss) per share
−Removed: income (loss) per share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the
−Removed: The calculation of diluted income (loss) per share does not consider the effect of the rights issued in connection with the Initial
−Removed: Public Offering and rights issued as components of the Private Placement Units (the “Private Rights”) since the issuance
−Removed: of shares underlying the rights are contingent upon the occurrence of future events.
−Removed: As a result, diluted loss per share is the same
−Removed: as basic loss per share for the periods.
−Removed: following table reflects the calculation of basic and diluted net income (loss) per ordinary share:
−Removed: of Basic and Diluted Net Income (Loss) Per Share
−Removed: SCHEDULE OF BASIC AND DILUTED NET INCOME (LOSS) PER
−Removed: For The Period from April 27, 2023 (Inception) Through December 31, 2023
−Removed: weighted average number of ordinary shares
+Added: As such, there was no provision
+Added: for income taxes for the years ended December 31, 2024 and 2023.
+Added: HEALTH TECHNOLOGY CO., LTD
+Added: TO FINANCIAL STATEMENTS
+Added: income per share
+Added: income per share is computed by dividing net income by the weighted average number of ordinary shares outstanding for the period.
+Added: calculation of diluted loss per share does not consider the effect of the rights issued in connection with the Initial Public Offering
+Added: and rights issued as components of the Private Units (the “Private Rights”) since the issuance of shares underlying the rights
+Added: is contingent upon the occurrence of future events.
+Added: As a result, diluted loss per share is the same as basic loss per share for the periods.
+Added: following table reflects the calculation of basic and diluted net income per ordinary share:
+Added: OF BASIC AND DILUTED NET INCOME PER ORDINARY SHARE
+Added: December 31, 2024
+Added: from April 27, 2023 (inception) to
+Added: December 31, 2023
+Added: including accretion of carrying value to redemption value
+Added: Non-Redeemable
+Added: Non-Redeemable
+Added: For the Year Ended
+Added: Period from April 27, 2023 (inception)
+Added: Non-Redeemable
+Added: Non-Redeemable
Basic and diluted net income per share:
+Added: of net income
+Added: Denominators:
+Added: Weighted-average shares outstanding
+Added: Basic and diluted net
+Added: income per share
Concentration
2 unchanged sentences
which, at times may exceed the Federal depository insurance coverage of $ 250,000 .
−Removed: As of December 31, 2023, the Company had not experienced
−Removed: losses on this account and management believes the Company is not exposed to significant risks on such account.
−Removed: As of December 31, 2023, $ 330,717 was not insured.
+Added: As of December 31, 2024 and 2023, the Company had not
+Added: experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
+Added: As of December
+Added: 31, 2024 and 2023, $ 0 and $ 330,717 was not insured, respectively.
value of financial instruments
6 unchanged sentences
These tiers include:
+Added: HEALTH TECHNOLOGY CO., LTD
+Added: TO FINANCIAL STATEMENTS
1 — defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
−Removed: 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted
−Removed: prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active;
−Removed: 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
−Removed: such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
+Added: 2 — defined as inputs other than quoted prices in active markets that are either directly
+Added: or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar
+Added: instruments in markets that are not active;
+Added: 3 — defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own
+Added: assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers
+Added: are unobservable.
some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy.
2 unchanged sentences
following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of December
−Removed: 31, 2023 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value:
+Added: 31, 2024 and 2023 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair
OF FAIR VALUE HIERARCHY VALUATION TECHNIQUES
−Removed: Quoted Prices in Active Markets (Level 1)
−Removed: Significant other Observable Inputs (Level 2)
−Removed: Significant other Unobservable Inputs (Level 3)
+Added: Quoted Prices
+Added: In Active Markets
+Added: in trust account
+Added: Quoted Prices
+Added: In Active Markets
marketable securities held in Trust Account
−Removed: Accounting Standards
−Removed: August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06,
−Removed: Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s
−Removed: Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments.
−Removed: ASU 2020-06 eliminates
−Removed: the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies
−Removed: the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity.
−Removed: The new standard
−Removed: also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s
−Removed: ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for
−Removed: all convertible instruments.
−Removed: The amendments are effective for smaller reporting companies for fiscal years beginning after December 15,
−Removed: 2023, including interim periods within those fiscal years.
−Removed: Early adoption is permitted, but no earlier than fiscal years beginning after
−Removed: December 15, 2020, including interim periods within those fiscal years.
−Removed: The Company adopted as of inception of the Company.
−Removed: does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a
−Removed: material effect on the Company’s financial statements.
+Added: which can be a corporation or individual, are considered to be related if either the Company or the other party has the ability, directly
+Added: or indirectly, to control the other party or exercise significant influence over the other party in making financial and operational
+Added: Companies are also considered to be related if they are subject to common control or significant influence.
+Added: issued accounting standards
+Added: November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280):
+Added: Improvements to Reportable Segment Disclosures.
+Added: The amendments
+Added: in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief
+Added: operating officer decision maker (“CODM”), as well as the aggregate amount of other segment items included in the reported
+Added: measure of segment profit or loss.
+Added: The ASU requires that a public entity disclose the title and position of the CODM and an explanation
+Added: of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate
+Added: Public entities will be required to provide all annual disclosures currently required by Topic 280 in interim periods, and
+Added: entities with a single reportable segment are required to provide all the disclosures required by the amendments in this ASU and existing
+Added: segment disclosures in Topic 280.
+Added: This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within
+Added: fiscal years beginning after December 15, 2024, with early adoption permitted.
+Added: does not believe that any other recently issued, but not effective, accounting standards, if currently adopted, would have a material
+Added: effect on the Company’s financial statements.
+Added: HEALTH TECHNOLOGY CO., LTD
+Added: TO FINANCIAL STATEMENTS
3 – INITIAL PUBLIC OFFERING
1 unchanged sentence
a result of the underwriter’s full exercise of its over-allotment option), at $ 10.00 per Unit, generating gross proceeds of $ 69,000,000 .
−Removed: Each Unit will one ordinary share and one right (“Public Right”).
−Removed: Each Public Right entitles the holder to receive one-fifth
−Removed: (1/5) of one Ordinary shares upon consummation of our initial business combination, so the holder must hold rights in multiples of 5
−Removed: in order to receive shares for all of the rights upon closing of a business combination.
−Removed: of December 31, 2023, the Company incurred offering costs of approximately $ 2,070,665
−Removed: and $ 690,000
−Removed: for deferred underwriting commissions.
+Added: Each Unit consists of one ordinary share and one right (“Public Right”).
+Added: Each Public Right entitles the holder to receive
+Added: one-fifth (1/5) of one ordinary share upon consummation of the Company’s initial business combination, so the holder must hold
+Added: rights in multiples of 5 in order to receive shares for all of the rights upon closing of a business combination.
4 – PRIVATE PLACEMENT
4 unchanged sentences
Units are identical to the Units sold in the Initial Public Offering except that Private Units (including the Private Rights) will not
−Removed: be transferable, assignable or salable until the completion of our initial business combination except to permitted transferees.
−Removed: Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Units will
−Removed: be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private rights will expire
+Added: be transferable, assignable or saleable until the completion of the Company’s initial business combination except to permitted
+Added: If the Company does not complete a business combination within the Combination Period, the proceeds from the sale of the
+Added: Private Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private
+Added: Rights will expire worthless.
5 – RELATED PARTY TRANSACTIONS
−Removed: to the IPO, the Company issued an aggregate of 50,000 ordinary shares of $ 1.00 par value each to Han Huang.
−Removed: On May 11, 2023, Han Huang
−Removed: transferred those ordinary shares to the sponsor and on May 15, 2023 the sponsor resolved to sub-divide the ordinary shares of $ 1.00
−Removed: par value each into ordinary shares of $ 0.0001 par value each and as such the sponsor held 500,000,000 ordinary shares of $ 0.0001 each.
−Removed: On May 15, 2023 the directors resolved to repurchase 498,562,500 ordinary shares from the sponsor, the repurchase resulting in the sponsor
−Removed: holding 1,437,500 ordinary shares.
−Removed: On May 25, 2023, 1,437,500 founder shares were issued to the sponsor (up to 187,500 of which are subject
−Removed: to forfeiture depending on the extent to which the underwriters’ over-allotment option is exercised) pursuant to a securities subscription
−Removed: agreement and the 1,437,500 ordinary shares previously held by the sponsor were repurchased by the company, the shares have been retroactively
−Removed: On October 20, 2023, the Company capitalized an amount equal to $ 28.75 standing to the credit of the share premium account
−Removed: and appropriated such sum and applied it on behalf of the Sponsor towards paying up in full (as to the full par value of $ 0.0001 per
−Removed: founder share) 287,500 unissued ordinary shares of $ 0.0001 par value and allotted such shares credited as fully paid to the Sponsor,
−Removed: resulting in 1,725,000 shares being issued and outstanding.
−Removed: 225,000 shares of such ordinary shares are not subject to forfeiture as the
−Removed: underwriters’ over-allotment was exercised in full.
−Removed: The initial shareholders will collectively own approximately 20 % of the Company’s
−Removed: issued and outstanding shares after the Initial public Offering (assuming the initial shareholders do not purchase any Public Shares
−Removed: in the Initial Public Offering and excluding the Private Units and underlying securities).
+Added: to the Initial Public Offering, the Company issued an aggregate of 50,000 ordinary shares of $ 1.00 par value each to Han Huang.
+Added: 11, 2023, Han Huang transferred those ordinary shares to the Sponsor and on May 15, 2023, the Sponsor resolved to sub-divide the ordinary
+Added: shares of $ 1.00 par value each into ordinary shares of $ 0.0001 par value each and as such the Sponsor held 500,000,000 ordinary shares
+Added: of $ 0.0001 each.
+Added: On May 15, 2023, the directors resolved to repurchase 498,562,500 ordinary shares from the Sponsor, the repurchase resulting
+Added: in the Sponsor holding 1,437,500 ordinary shares.
+Added: On May 25, 2023, 1,437,500 founder shares were issued to the Sponsor (up to 187,500
+Added: of which are subject to forfeiture depending on the extent to which the underwriters’ over-allotment option is exercised) pursuant
+Added: to a securities subscription agreement and the 1,437,500 ordinary shares previously held by the Sponsor were repurchased by the company,
+Added: the shares have been retroactively adjusted.
+Added: On October 20, 2023, the Company capitalized an amount equal to $ 28.75 standing to the credit
+Added: of the share premium account and appropriated such sum and applied it on behalf of the Sponsor towards paying up in full (as to the full
+Added: par value of $ 0.0001 per founder share) 287,500 unissued ordinary shares of $ 0.0001 par value and allotted such shares credited as fully
+Added: paid to the Sponsor, resulting in 1,725,000 ordinary shares being issued and outstanding.
+Added: 225,000 shares of such ordinary shares are
+Added: not subject to forfeiture as the underwriters’ over-allotment was exercised in full.
+Added: The initial shareholders will collectively
+Added: own approximately 20 % of the Company’s issued and outstanding shares after the Initial Public Offering (assuming the initial shareholders
+Added: do not purchase any Public Shares in the Initial Public Offering and excluding the Private Units and underlying securities).
to certain limited exceptions, the initial shareholders have agreed not to transfer, assign or sell their founder shares until six months
−Removed: after the date of the consummation of our initial business combination or earlier if, subsequent to initial business combination, the
−Removed: Company consummate a subsequent liquidation, merger, share exchange or other similar transaction which results in all of the shareholders
−Removed: having the right to exchange their ordinary shares for cash, securities or other property.
+Added: after the date of the consummation of the Company’s initial business combination or earlier if, subsequent to initial business
+Added: combination, the Company consummate a subsequent liquidation, merger, share exchange or other similar transaction which results in all
+Added: of the shareholders having the right to exchange their ordinary shares for cash, securities or other property.
Note – Related Party
−Removed: May 1, 2023, the Sponsor issued an unsecured promissory note to the Company, pursuant to which the Company may borrow up to an aggregate
−Removed: principal amount of $ 750,000 , to be used for payment of costs related to the Initial Public Offering.
−Removed: The note is non-interest bearing
−Removed: and payable on the earlier of (i) December 31, 2023, (ii) the consummation of the Initial Public Offering or (iii) the date on which
−Removed: the Company determines to not proceed with the Initial Public Offering.
−Removed: These amounts were repaid upon completion of the Initial Public
−Removed: Offering out of the $ 550,000 of Initial Public Offering proceeds that has been allocated for the payment of Initial Public Offering expenses.
−Removed: As of December 6, 2023, the Company has borrowed $ 210,151 under the promissory note with our Sponsor.
−Removed: This promissory note was fully
−Removed: repaid on December 7, 2023.
−Removed: There is no outstanding balance due as of December 31, 2023.
+Added: May 1, 2023, the Sponsor issued an unsecured promissory note (the “Note”) to the Company, pursuant to which the Company may
+Added: borrow up to an aggregate principal amount of $ 750,000 , to be used for payment of costs related to the Initial Public Offering.
+Added: is non-interest bearing and payable on the earlier of (i) December 31, 2023, (ii) the consummation of the Initial Public Offering, or
+Added: (iii) the date on which the Company determines to not proceed with the Initial Public Offering.
+Added: These amounts were repaid upon completion
+Added: of the Initial Public Offering out of the $ 550,000 of Initial Public Offering proceeds that has been allocated for the payment of Initial
+Added: Public Offering expenses.
+Added: As of December 6, 2023, the Company has borrowed $ 210,151 under the Note.
+Added: The Note was fully repaid on December
+Added: There was no outstanding balance due as of December 31, 2024 and 2023.
+Added: HEALTH TECHNOLOGY CO., LTD
+Added: TO FINANCIAL STATEMENTS
+Added: Loan – Related Party
+Added: Company will have to consummate a business combination by April 6, 2025.
+Added: However, if the Company anticipates that it may not be able
+Added: to consummate a business combination within 12 months, the Company may extend the period of time to consummate a business combination
+Added: up to twelve times by an additional one month each time to complete a business combination.
+Added: Pursuant to the terms of the Company’s
+Added: memorandum and articles of association and the trust agreement entered into between the Company and Continental Stock Transfer &
+Added: Trust Company, both as amended, in order to extend the time available for the Company to consummate a business combination, the Sponsor
+Added: its affiliates or designees, upon five days advance notice prior to the applicable deadline, must deposit into the Trust Account the
+Added: applicable extension fees, on or prior to the date of the applicable deadline, for each extension.
+Added: The Sponsor or its affiliates or designees
+Added: will receive a non-interest bearing, unsecured promissory note equal to the amount of any such deposit that will not be repaid in the
+Added: event that the Company are unable to close a business combination unless there are funds available outside the Trust Account to do so.
+Added: Such notes would either be paid upon consummation of the Company’s initial business combination or at the lender’s discretion,
+Added: converted upon consummation of the business combination into additional private units at a price of $ 10.00 per unit.
+Added: December 11, 2024, the Company issued an unsecured promissory note in the amount of $ 227,700 to the Sponsor and United Hydrogen, pursuant
+Added: to which such amount had been deposited into the Trust Account in order to extend the amount of available time to complete a business
+Added: combination until January 6, 2025.
+Added: The notes are non-interest bearing and are payable upon the closing of a business combination.
+Added: addition, the notes may be converted, at the lender’s discretion, into additional Private Units at a price of $ 10.00 per unit.
+Added: As of December 31, 2024 and 2023, the note payable balance was $ 227,700 and $ 0 , respectively.
order to finance transaction costs in connection with a business combination, the Company’s Sponsor or an affiliate of the Sponsor,
8 unchanged sentences
held in the Trust Account would be used to repay the Working Capital Loans.
−Removed: As of December 31, 2023, there was no amount outstanding
+Added: As of December 31, 2024 and 2023, there was no amount outstanding
under any Working Capital Loan.
+Added: to a related company
+Added: of December 31, 2024 and 2023, the Company had a total amount due to related company of $ 289,780 and $ 0 from a related party, respectively,
+Added: for the payment of costs related to general and administrative services, the Initial Public Offering and administrative services agreement.
+Added: The balance of which $ 50,000 was deposited in the trust account as of December 31, 2024 for the January 13, 2025 extension payment.
+Added: balance is unsecured, interest-free and has no fixed terms of repayment.
Administrative
Services Arrangement
−Removed: affiliate of our Sponsor has agreed, commencing from the date that the Company’s securities are first listed on Nasdaq,
−Removed: through the earlier of the Company’s consummation of a Business Combination and its liquidation, to make available to the
−Removed: Company our Sponsor certain general and administrative services, including office space, utilities and administrative services, as
−Removed: the Company may require from time to time.
−Removed: The Company has agreed to pay to the affiliate of our Sponsor, $ 10,000
−Removed: per month, for up to 12 months, subject to extension to up to 24 months, as provided in the Company’s registration statement,
−Removed: for such administrative services.
−Removed: For the period from inception through December 31, 2023, $ 10,000 is charged
−Removed: to expenses and included in the accrued expense on balance sheet as of December 31, 2023.
+Added: Sponsor has agreed, commencing from the date that the Company’s securities are first listed on Nasdaq, through the earlier of the
+Added: Company’s consummation of a business combination and its liquidation, to make available to the Company certain general and administrative
+Added: services, including office space, utilities and administrative services, as the Company may require from time to time.
+Added: The Company has
+Added: agreed to pay to the Sponsor, $ 10,000 per month, for up to 12 months, subject to extension to up to 24 months, as provided in the Company’s
+Added: registration statement, for such administrative services.
+Added: As of December 31, 2024 and 2023, the unpaid balance was $ 120,000 and $ 0 , respectively,
+Added: which is included in amount due to related company balance.
+Added: HEALTH TECHNOLOGY CO., LTD
+Added: TO FINANCIAL STATEMENTS
+Added: 6 – SHAREHOLDERS’ DEFICIT
+Added: Company is authorized to issue 500,000,000 ordinary shares with a par value of $ 0.0001 per share.
+Added: Holders of the Company’s ordinary
+Added: shares are entitled to one vote for each share.
+Added: On May 1, 2023, The Company entered into a subscription agreement for founder shares
+Added: with the Sponsor which is recorded as subscription receivable.
+Added: The subscription agreement was amended and restated on May 24, 2023.
+Added: to the Initial Public Offering, the Company issued an aggregate of 50,000 ordinary shares of $ 1.00 par value each to Han Huang.
+Added: 11, 2023, Han Huang transferred those ordinary shares to the Sponsor and on May 15, 2023, the Sponsor resolved to sub-divide the ordinary
+Added: shares of $ 1.00 par value each into ordinary shares of $ 0.0001 par value each and as such the Sponsor held 500,000,000 ordinary shares
+Added: of $ 0.0001 each.
+Added: On May 15, 2023, the directors resolved to repurchase 498,562,500 ordinary shares from the Sponsor, the repurchase resulting
+Added: in the Sponsor holding 1,437,500 ordinary shares.
+Added: On May 25, 2023, 1,437,500 founder shares were issued to the Sponsor pursuant to a
+Added: securities subscription agreement for an aggregate purchase price of $ 25,000 (up to 187,500 of which are subject to forfeiture depending
+Added: on the extent to which the underwriters’ over-allotment option is exercised) pursuant to a securities subscription agreement and
+Added: the 1,437,500 ordinary shares previously held by the Sponsor were repurchased by the Company, the shares having been retroactively adjusted.
+Added: As of May 8, 2023, $ 25,000 was included as a subscription receivable.
+Added: On September 15, 2023, the Company received $ 25,000 in cash.
+Added: Sponsor transferred 152,000 of those ordinary shares among the Company’s Chief Executive Officer, Chief Financial Officer and three
+Added: independent director nominees at their original purchase price pursuant to executed securities assignment agreements, effective as of
+Added: May 25, 2023.
+Added: On October 20, 2023, the Company capitalized an amount equal to $ 28.75 standing to the credit of the share premium account
+Added: and appropriated such sum and applied it on behalf of the Sponsor towards paying up in full (as to the full par value of $ 0.0001 per
+Added: founder share) 287,500 unissued ordinary shares of $ 0.0001 par value and allotted such shares credited as fully paid to the Sponsor,
+Added: resulting in 1,725,000 ordinary shares being issued and outstanding.
+Added: 225,000 shares of such ordinary shares are not subject to forfeiture
+Added: as the underwriters’ over-allotment was exercised in full.
+Added: The initial shareholders will collectively own approximately 20 % of
+Added: the Company’s issued and outstanding shares after the Initial Public Offering (assuming the initial shareholders do not purchase
+Added: any Public Shares in the Initial Public Offering and excluding the Private Units and underlying securities).
+Added: of December 31, 2024 and 2023, as a result of the closing of the Initial Public Offering and full exercise of the underwriters’
+Added: over-allotment option, there were 2,126,000 ordinary shares issued and outstanding, excluding 6,900,000 ordinary shares subject to possible
+Added: holder of a right will receive one-fifth (1/5) of one ordinary share upon consummation of a business combination, even if the holder
+Added: of such right redeemed all shares held by it in connection with a business combination.
+Added: No fractional shares will be issued upon exchange
+Added: of the rights.
+Added: No additional consideration will be required to be paid by a holder of rights in order to receive its additional shares
+Added: upon consummation of a business combination as the consideration related thereto has been included in the unit purchase price paid for
+Added: by investors in the Initial Public Offering.
+Added: If the Company enters into a definitive agreement for a business combination in which the
+Added: Company will not be the surviving entity, the definitive agreement will provide for the holders of rights to receive the same per share
+Added: consideration the holders of the ordinary share will receive in the transaction on an as-converted into ordinary share basis and each
+Added: holder of a right will be required to affirmatively convert its rights in order to receive 1/5th of one share underlying each right (without
+Added: paying additional consideration).
+Added: The shares issuable upon exchange of the rights will be freely tradable (except to the extent held
+Added: by affiliates of the Company).
+Added: Additionally,
+Added: in no event will the Company be required to net cash to settle the rights.
+Added: If the Company is unable to complete a business combination
+Added: within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of rights will not receive any
+Added: of such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of the
+Added: Trust Account with respect to such rights.
+Added: Accordingly, the rights may expire worthless.
+Added: HEALTH TECHNOLOGY CO., LTD
+Added: TO FINANCIAL STATEMENTS
7 – COMMITMENTS AND CONTINGENCIES
8 unchanged sentences
The Company will bear the expenses incurred in connection with the filing of any such registration statements.
−Removed: Representative
−Removed: Company issued 69,000 representative shares to the representative (and/or its designees) as part of representative compensation as the
−Removed: underwriters exercised their over-allotment option in full.
−Removed: The representative shares have been deemed compensation by FINRA and are
−Removed: therefore subject to a lock-up for a period of 180 days immediately following the date of the commencement of sales in the IPO pursuant
−Removed: to FINRA Rule 5110 (e)(1).
−Removed: Pursuant to FINRA Rule 5110(e)(1), these securities will not be the subject of any hedging, short sale, derivative,
−Removed: put or call transaction that would result in the economic disposition of the securities by any person for a period of 180 days immediately
−Removed: following the date of the commencement of sales in the IPO, nor may they be sold, transferred, assigned, pledged or hypothecated for
−Removed: a period of 180 days immediately following the date of the commencement of sales in the IPO except to any underwriter and selected dealer
−Removed: participating in the offering and their officers, partners, registered persons or affiliates.
initial shareholders and their permitted transferees can demand that the Company register the founder shares, the Private Units and the
1 unchanged sentence
pursuant to an agreement to be signed prior to or on the effective date requiring the Company to register such securities for resale.
−Removed: The holders of such securities are entitled to demand
−Removed: that the Company register these securities at any time after consummation of an initial business combination.
−Removed: Notwithstanding anything
−Removed: to the contrary, any holder that is affiliated with an underwriter participating in the IPO may only make a demand on one occasion and
−Removed: only during the five-year period beginning on the effective date of the registration statement.
−Removed: In addition, the holders have certain “piggy-back” registration rights on registration statements filed after our consummation
−Removed: of a business combination;
−Removed: provided that any holder that is affiliated with an underwriter participating in the IPO may participate in
−Removed: a “piggy-back” registration only during the seven-year period beginning on the effective date of the registration statement.
−Removed: underwriters purchased the 900,000 of additional Units to cover over-allotments, less the underwriting discounts and commissions.
+Added: The holders of such securities are entitled to demand that the Company register these securities at any time after consummation of an
+Added: initial business combination.
+Added: Notwithstanding anything to the contrary, any holder that is affiliated with an underwriter participating
+Added: in the Initial Public Offering may only make a demand on one occasion and only during the five-year period beginning on the effective
+Added: date of the registration statement.
+Added: In addition, the holders have certain “piggy-back” registration rights on registration
+Added: statements filed after the Company’s consummation of a business combination;
+Added: provided that any holder that is affiliated with an
+Added: underwriter participating in the Initial Public Offering may participate in a “piggy-back” registration only during the seven-year
+Added: period beginning on the effective date of the registration statement.
+Added: Representative
+Added: Company issued 69,000 ordinary shares to the representative (and/or its designees) (the “representative shares”) as part
+Added: of representative compensation as the underwriters exercised their over-allotment option in full.
+Added: The representative shares have been
+Added: deemed compensation by FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the date of the commencement
+Added: of sales in the Initial Public Offering pursuant to FINRA Rule 5110 (e)(1).
+Added: Pursuant to FINRA Rule 5110(e)(1), these securities will
+Added: not be the subject of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition of the
+Added: securities by any person for a period of 180 days immediately following the date of the commencement of sales in the Initial Public Offering,
+Added: nor may they be sold, transferred, assigned, pledged or hypothecated for a period of 180 days immediately following the date of the commencement
+Added: of sales in the Initial Public Offering except to any underwriter and selected dealer participating in the offering and their officers,
+Added: partners, registered persons or affiliates.
+Added: underwriters purchased 900,000 additional Units to cover over-allotments.
underwriters were entitled to a cash underwriting discount of:
7 unchanged sentences
In addition, the Company has paid the
−Removed: representative of the underwriters, at closing of the Initial Public Offering, 1.00 % of the gross proceeds in the Company’s ordinary
−Removed: shares or 69,000 ordinary shares as the underwriters’ over-allotment is exercised in full.
+Added: representative of the underwriters, at the closing of the Initial Public Offering, 1.00 % of the gross proceeds in the Company’s
+Added: ordinary shares or 69,000 ordinary shares as the underwriters’ over-allotment is exercised in full.
of First Refusal
a period beginning on the closing of the Initial Public Offering and ending 12 months from the closing of a business combination, the
−Removed: Company has granted Spartan Capital Securities, LLC, a right of first refusal to act as sole investment banker, sole book running manager
−Removed: and/or sole placement agent for any and all future private or public equity, equity-linked, convertible and debt offerings during such
−Removed: In accordance with FINRA Rule 5110(g)(6)(A), such right of first refusal shall not have a duration of more than three years from
−Removed: the commencement of sales in the IPO.
−Removed: STOCKHOLDERS’ EQUITY
−Removed: share — The Company is authorized to issue 500,000,000 ordinary shares with a par value of $ 0.0001 per share.
−Removed: the Company’s ordinary shares are entitled to one vote for each share.
−Removed: On May 1, 2023, we entered into a subscription agreement
−Removed: for founder shares with our sponsor which is recorded as subscription receivable and which was amended and restated on May 24, 2023.
−Removed: Prior to the IPO, the Company issued an aggregate of 50,000 ordinary shares of $ 1.00 par value each to Han Huang.
−Removed: On May 11, 2023, Han
−Removed: Huang transferred those ordinary shares to the sponsor and on May 15, 2023, the sponsor resolved to sub-divide the ordinary shares of
−Removed: $ 1.00 par value each into ordinary shares of $ 0.0001 par value each and as such the sponsor held 500,000,000 ordinary shares of $ 0.0001
−Removed: On May 15, 2023, the directors resolved to repurchase 498,562,500 ordinary shares from the sponsor, the repurchase resulting in
−Removed: the sponsor holding 1,437,500 ordinary shares.
−Removed: On May 25, 2023, 1,437,500 founder shares were issued to the sponsor pursuant to a securities
−Removed: subscription agreement for an aggregate purchase price of $ 25,000 (up to 187,500 of which are subject to forfeiture depending on the
−Removed: extent to which the underwriters’ over-allotment option is exercised) pursuant to a securities subscription agreement and the 1,437,500
−Removed: ordinary shares previously held by the sponsor were repurchased by the company, the shares have been retroactively adjusted.
−Removed: 8, 2023, $ 25,000 was included as a subscription receivable.
−Removed: On September 15, 2023, the Company received $ 25,000 in cash.
−Removed: transferred 152,000 of those ordinary shares among the Company’s Chief Executive Officer, Chief Financial Officer and three independent
−Removed: director nominees at their original purchase price pursuant to executed securities assignment agreements, effective as of May 25, 2023.
−Removed: On October 20, 2023, the Company capitalized an amount equal to $ 28.75 standing to the credit of the share premium account and appropriated
−Removed: such sum and applied it on behalf of the Sponsor towards paying up in full (as to the full par value of $ 0.0001 per founder share) 287,500
−Removed: unissued ordinary shares of $ 0.0001 par value and allotted such shares credited as fully paid to the Sponsor, resulting in 1,725,000
−Removed: shares being issued and outstanding.
−Removed: 225,000 shares of such ordinary shares are not subject to forfeiture as the underwriters’
−Removed: over-allotment was exercised in full.
−Removed: The initial shareholders will collectively own approximately 20 % of the Company’s issued
−Removed: and outstanding shares after the Initial public Offering (assuming the initial shareholders do not purchase any Public Shares in the
−Removed: Initial Public Offering and excluding the Private Units and underlying securities).
−Removed: of December 31, 2023, as a result of closing of the IPO and full exercise of the Representative’s Over-Allotment Option, there
−Removed: were 2,126,000 ordinary shares issued and outstanding, excluding 6,900,000 ordinary shares subject to possible redemption.
−Removed: — Each holder of a right will receive one-fifth (1/5) of one ordinary share upon consummation of a Business Combination,
−Removed: even if the holder of such right redeemed all shares held by it in connection with a Business Combination.
−Removed: No fractional shares will
−Removed: be issued upon exchange of the rights.
−Removed: No additional consideration will be required to be paid by a holder of rights in order to receive
−Removed: its additional shares upon consummation of a Business Combination as the consideration related thereto has been included in the unit
−Removed: purchase price paid for by investors in the Initial Public Offering.
−Removed: If the Company enters into a definitive agreement for a Business
−Removed: Combination in which the Company will not be the surviving entity, the definitive agreement will provide for the holders of rights to
−Removed: receive the same per share consideration the holders of the ordinary share will receive in the transaction on an as- converted into ordinary
−Removed: share basis and each holder of a right will be required to affirmatively convert its rights in order to receive 1/5th of one share underlying
−Removed: each right (without paying additional consideration).
−Removed: The shares issuable upon exchange of the rights will be freely tradable (except
−Removed: to the extent held by affiliates of the Company).
−Removed: Additionally,
−Removed: in no event will the Company be required to net cash settle the rights.
−Removed: If the Company is unable to complete a Business Combination within
−Removed: the Combination Period and the Company liquidates the funds held in the Trust Account, holders of rights will not receive any of such
−Removed: funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of the Trust
−Removed: Account with respect to such rights.
−Removed: Accordingly, the rights may expire worthless.
+Added: Company has granted Spartan Capital Securities, LLC, a right of first refusal to act as the sole investment banker, sole book running
+Added: manager and/or sole placement agent for any and all future private or public equity, equity-linked, convertible and debt offerings during
+Added: In accordance with FINRA Rule 5110(g)(6)(A), such right of first refusal shall not have a duration of more than three years
+Added: from the commencement of sales in the Initial Public Offering.
+Added: HEALTH TECHNOLOGY CO., LTD
+Added: TO FINANCIAL STATEMENTS
+Added: 8 – SEGMENT INFORMATION
+Added: Topic 280, “Segment Reporting,” establishes standards for companies to report in their financial statement information about
+Added: operating segments, products, services, geographic areas, and major customers.
+Added: Operating segments are defined as components of an enterprise
+Added: for which separate financial information is available that is regularly evaluated by the Company’s chief operating decision maker,
+Added: or group, in deciding how to allocate resources and assess performance.
+Added: Company’s chief operating decision maker has been identified as the Chief Financial Officer (“CODM”), who reviews the
+Added: operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance.
+Added: management has determined that the Company only has one operating segment.
+Added: evaluating the Company’s performance and making key decisions regarding resource allocation, the CODM reviews several key metrics,
+Added: which includes general and administrative expenses and interest earned on assets held in Trust Account which are included in the accompanying
+Added: statements of operations.
+Added: key measures of segment profit or loss reviewed by our CODM are earned on assets held in Trust Account and general and administrative
+Added: The CODM reviews earned on assets held in Trust Account to measure and monitor stockholder value and determine the most effective
+Added: strategy of investment with the Trust Account funds while maintaining compliance with the trust agreement.
+Added: General and administrative
+Added: expenses are reviewed and monitored by the CODM to manage and forecast cash to ensure enough capital is available to complete a business
+Added: combination within the business combination period.
+Added: The CODM also reviews general and administrative costs to manage, maintain and enforce
+Added: all contractual agreements to ensure costs are aligned with all agreements and budget.
9 – SUBSEQUENT EVENTS
accordance with ASC Topic 855, “ Subsequent Events ”, which establishes general standards of accounting for and disclosure
−Removed: of events that occur after the balance sheet date but before financial statements are issued, the Company has evaluated all events or
−Removed: transactions that occurred through the date the financial statements were available to issue.
−Removed: Based upon this review, the Company
−Removed: did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.
+Added: of events that occur after the balance sheet date, the Company has evaluated all events or transactions that occurred after the balance
+Added: sheet date through the date the financial statements were issued.
+Added: January 13, 2025, the Company issued an unsecured promissory note in an amount of $ 227,700 to the Sponsor and United Hydrogen, pursuant
+Added: to which such amount had been deposited into the Trust Account in order to extend the amount of available time to complete a business
+Added: combination until February 6, 2025.
+Added: February 5, 2025, in connection with the stockholders vote at the Adjourned Meeting, 2,904,267 shares were redeemed by certain shareholders
+Added: at a price of approximately $ 10.77 per share, including interest generated and extension payments deposited in the Trust Account, in
+Added: an aggregate amount of approximately $ 31.27 million.
+Added: February 6, 2025, the Company entered into the Trust Agreement Amendment with the Trustee.
+Added: Pursuant to the Trust Agreement Amendment,
+Added: the amount of funds to be deposited into the Trust Account in connection with extending the timeframe within which the Company must consummate
+Added: its initial business combination, is adjusted from $ 0.033 per each Public Share (for each monthly extension) to an amount equal to $ 150,000
+Added: for all outstanding Public Shares (for each monthly extension).
+Added: February 6, 2025, the Company issued an unsecured promissory note in an amount of $ 150,000 to the Sponsor and United Hydrogen, pursuant
+Added: to which such amount had been deposited into the Trust Account in order to extend the amount of available time to complete a business
+Added: combination until March 6, 2025.
+Added: March 6, 2025, the Company issued an unsecured promissory note in an amount of $ 150,000 to the Sponsor and United Hydrogen, pursuant
+Added: to which such amount had been deposited into the Trust Account in order to extend the amount of available time to complete a business
+Added: combination until April 6, 2025.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.